<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants - Mitra, S - 2020 | Cochrane Library</title> <meta content="Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants - Mitra, S - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013278.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants - Mitra, S - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013278.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013278.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants" name="citation_title"/> <meta content="Souvik Mitra" name="citation_author"/> <meta content="Dalhousie University &amp; IWK Health Centre" name="citation_author_institution"/> <meta content="souvik.mitra@iwk.nshealth.ca" name="citation_author_email"/> <meta content="Alexandra Scrivens" name="citation_author"/> <meta content="Oxford University Hospitals NHS Foundation Trust" name="citation_author_institution"/> <meta content="Adelaide M von Kursell" name="citation_author"/> <meta content="Dalhousie University" name="citation_author_institution"/> <meta content="Tim Disher" name="citation_author"/> <meta content="EVERSANA Inc" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD013278.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/12/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013278.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013278.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013278.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Inflammatory Agents, Non-Steroidal [adverse effects, *therapeutic use]; Cause of Death; Cerebral Intraventricular Hemorrhage [epidemiology]; Chronic Disease; Ductus Arteriosus, Patent [mortality, *therapy]; Enterocolitis, Necrotizing [epidemiology]; Hemodynamics; Ibuprofen [adverse effects, therapeutic use]; Indomethacin [adverse effects, therapeutic use]; Infant, Premature; Ligation [methods]; Lung Diseases [epidemiology]; Pneumothorax; Randomized Controlled Trials as Topic; Time Factors; Time-to-Treatment; *Watchful Waiting" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013278.pub2&amp;doi=10.1002/14651858.CD013278.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="77cjsSG8";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013278\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013278\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ko","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013278.pub2",title:"Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants",firstPublishedDate:"Dec 10, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013278.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013278.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013278.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013278.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013278.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013278.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013278.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013278.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013278.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013278.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6293 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013278.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-sec-0143"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-sec-0137"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/appendices#CD013278-sec-0148"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/table_n/CD013278StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/table_n/CD013278StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/information#CD013278-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Souvik Mitra</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/information#CD013278-cr-0005">Alexandra Scrivens</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/information#CD013278-cr-0006">Adelaide M von Kursell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013278.pub2/information#CD013278-cr-0007">Tim Disher</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/information/en#CD013278-sec-0169">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 December 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013278.pub2">https://doi.org/10.1002/14651858.CD013278.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013278-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013278-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013278-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013278-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013278-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013278-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013278-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013278-abs-0001" lang="en"> <section id="CD013278-sec-0001"> <h3 class="title" id="CD013278-sec-0001">Background</h3> <p>Patent ductus arteriosus (PDA) is associated with significant morbidity and mortality in preterm infants. Nonsteroidal anti‐inflammatory drugs (NSAIDs) are used to prevent or treat a PDA. There are concerns regarding adverse effects of NSAIDs in preterm infants. Controversy exists on whether early targeted treatment of a hemodynamically significant (hs) PDA improves clinical outcomes. </p> </section> <section id="CD013278-sec-0002"> <h3 class="title" id="CD013278-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of early treatment strategies versus expectant management for an hs‐PDA in reducing mortality and morbidity in preterm infants. </p> </section> <section id="CD013278-sec-0003"> <h3 class="title" id="CD013278-sec-0003">Search methods</h3> <p>We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2019, Issue 6) in the Cochrane Library; MEDLINE via PubMed (1966 to 31 May 2019), Embase (1980 to 31 May 2019), and CINAHL (1982 to 31 May 2019). An updated search was run on 2 October 2020 in the following databases: CENTRAL via CRS Web and MEDLINE via Ovid. We searched clinical trial databases, conference proceedings, and the reference lists of retrieved articles for randomized controlled trials (RCT) and quasi‐randomized trials. </p> </section> <section id="CD013278-sec-0004"> <h3 class="title" id="CD013278-sec-0004">Selection criteria</h3> <p>We included RCTs in which early pharmacological treatment, defined as treatment initiated within the first seven days after birth, was compared to no intervention, placebo or other non‐pharmacological expectant management strategies for treatment of an hs‐PDA in preterm (&lt; 37 weeks’ postmenstrual age) or low birth weight (&lt; 2500 grams) infants. </p> </section> <section id="CD013278-sec-0005"> <h3 class="title" id="CD013278-sec-0005">Data collection and analysis</h3> <p>We performed data collection and analyses in accordance with the methods of Cochrane Neonatal. Our primary outcome was all‐cause mortality during hospital stay. We used the GRADE approach to assess the certainty of evidence for selected clinical outcomes. </p> </section> <section id="CD013278-sec-0006"> <h3 class="title" id="CD013278-sec-0006">Main results</h3> <p>We included 14 RCTs that enrolled 910 infants. Seven RCTs compared early treatment (defined as treatment initiated by seven days of age) versus expectant management and seven RCTs compared very early treatment (defined as treatment initiated by 72 hours of age) versus expectant management. </p> <p>No difference was demonstrated between early treatment versus expectant management (no treatment initiated within the first seven days after birth) for an hs‐PDA for the primary outcome of ‘all‐cause mortality’ (6 studies; 500 infants; typical RR 0.80, 95% CI 0.46 to 1.39; typical RD ‐0.02; 95% CI ‐0.07 to 0.03; moderate‐certainty evidence), or other important outcomes such as surgical PDA ligation (4 studies; 432 infants; typical RR 1.08, 95% CI 0.65 to 1.80; typical RD ‐0.03; 95% CI ‐0.09 to 0.03; very low‐certainty evidence), chronic lung disease (CLD) (4 studies; 339 infants; typical RR 0.90, 95% CI 0.62 to 1.29; typical RD ‐0.03; 95% CI ‐0.10 to 0.03; moderate‐certainty evidence), severe intraventricular hemorrhage (IVH) (2 studies; 171 infants; typical RR 0.83,95% CI 0.32 to 2.16; typical RD ‐0.01; 95% CI ‐0.08 to 0.06; low‐certainty evidence), and necrotizing enterocolitis (NEC) (5 studies; 473 infants; typical RR 2.34,95% CI 0.86 to 6.41; typical RD 0.04; 95% CI 0.01 to 0.08; low‐certainty evidence). Infants receiving early treatment in the first seven days after birth were more likely to receive any PDA pharmacotherapy compared to expectant management (2 studies; 232 infants; typical RR 2.30, 95% CI 1.86 to 2.83; typical RD 0.57; 95% CI 0.48 to 0.66; low‐certainty evidence). </p> <p>No difference was demonstrated between very early treatment versus expectant management (no treatment initiated within the first 72 hours after birth) for an hs‐PDA for the primary outcome of ‘all‐cause mortality’ (7 studies; 384 infants; typical RR 0.94, 95% CI 0.58 to 1.53; typical RD ‐0.03; 95% CI ‐0.09 to 0.04; moderate‐certainty evidence) or other important outcomes such as surgical PDA ligation (5 studies; 293 infants; typical RR 0.88, 95% CI 0.36 to 2.17; typical RD ‐0.01; 95% CI ‐0.05 to 0.02; moderate‐certainty evidence), CLD (7 studies; 384 infants; typical RR 0.83, 95% CI 0.63 to 1.08; typical RD ‐0.05; 95% CI ‐0.13 to 0.04; low‐certainty evidence), severe IVH (4 studies, 240 infants; typical RR 0.64, 95% CI 0.21 to 1.93; typical RD ‐0.02; 95% CI ‐0.07 to 0.04; moderate‐certainty evidence), NEC (5 studies; 332 infants; typical RR 1.08, 95% CI 0.53 to 2.21; typical RD 0.01; 95% CI ‐0.04 to 0.06; moderate‐certainty evidence) and neurodevelopmental impairment (1 study; 79 infants; RR 0.27, 95% CI 0.03 to 2.31 for moderate/severe cognitive delay at 18 to 24 months; RR 0.54, 95% CI 0.05 to 5.71 for moderate/severe motor delay at 18 to 24 months; RR 0.54, 95% CI 0.10 to 2.78 for moderate/severe language delay at 18 to 24 months; low‐certainty evidence). Infants receiving very early treatment in the first 72 hours after birth were more likely to receive any PDA pharmacotherapy compared to expectant management (4 studies; 156 infants; typical RR 1.64, 95% CI 1.31 to 2.05; typical RD 0.69; 95% CI 0.60 to 0.79; very low‐certainty evidence). Very early treatment, however, shortened the duration of hospitalization compared to expectant management (4 studies; 260 infants; MD ‐5.35 days; 95% CI ‐9.23 to ‐1.47; low‐certainty evidence). </p> </section> <section id="CD013278-sec-0007"> <h3 class="title" id="CD013278-sec-0007">Authors' conclusions</h3> <p>Early or very early pharmacotherapeutic treatment of an hs‐PDA probably does not reduce mortality in preterm infants (moderate‐certainty evidence). Early pharmacotherapeutic treatment of hs‐PDA may increase NSAID exposure (low‐certainty evidence) without likely reducing CLD (moderate‐certainty evidence), severe IVH or NEC (low‐certainty evidence). We are uncertain whether very early pharmacotherapeutic treatment of hs‐PDA also increases NSAID exposure (very low‐certainty evidence). Very early treatment probably does not reduce surgical PDA ligation, severe IVH or NEC (moderate‐certainty evidence), and may not reduce CLD or neurodevelopmental impairment (low‐certainty evidence). Additional large trials that specifically include preterm infants at the highest risk of PDA‐attributable morbidity, are adequately powered for patient‐important outcomes and are minimally contaminated by open‐label treatment are required to explore if early targeted treatment of hs‐PDA improves clinical outcomes. There are currently two trials awaiting classification and two ongoing trials exploring this question. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013278-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013278-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013278-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013278-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013278-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013278-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013278-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013278-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013278-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013278-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013278-abs-0002" lang="en"> <h3>Early treatment versus expectant management of symptomatic patent ductus arteriosus in preterm infants </h3> <p><b>Review question</b> </p> <p>Does early treatment (initiated within the first seven days after birth) or very early treatment (initiated within the first 72 hours after birth) of a symptomatic patent ductus arteriosus (PDA) with nonsteroidal anti‐inflammatory drugs (NSAIDs) compared to expectant management (without use of NSAIDs) improve outcomes in preterm infants? </p> <p><b>Background</b> </p> <p>PDA is a common complication in preterm or low birth weight infants. PDA is an open vascular channel between the lungs and the heart which usually closes shortly after birth. In preterm infants, the PDA often remains open and may contribute to life‐threatening complications. Medications such as NSAIDs are used to prevent or treat a PDA before it becomes symptomatic. However, there are concerns regarding the side‐effects of NSAIDs in preterm infants. There is controversy on whether early treatment of a symptomatic PDA improves outcomes in preterm infants. </p> <p><b>Study characteristics</b> </p> <p>We searched scientific databases for randomized controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) in preterm (born at less than 37 weeks into pregnancy) or low‐birth‐weight (weighing less than 2500 grams) infants with a symptomatic PDA diagnosed using a combination of specific clinical features and ultrasound of the heart. The included studies compared early treatment, or very early treatment of a symptomatic PDA with NSAIDs compared to expectant management without the use of NSAIDs. The search is up to date as of 2 October 2020. </p> <p><b>Key results</b> </p> <p>This review of 14 clinical trials (910 infants) found that early or very early treatment of a symptomatic PDA does not reduce death or other poor clinical outcomes in preterm infants. Early or very early treatment, on the other hand, appears to increase the number of preterm infants exposed to NSAIDs. There are currently two trials awaiting classification and two ongoing trials exploring this question. </p> <p><b>Certainty of evidence</b> </p> <p>According to GRADE (a method to score the certainty of the trials supporting each outcome), the certainty of the evidence varied from very low to moderate but was moderate for the most important outcome of death. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013278-sec-0143" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013278-sec-0143"></div> <h3 class="title" id="CD013278-sec-0144">Implications for practice</h3> <section id="CD013278-sec-0144"> <p>Moderate‐certainty evidence suggests that early or very early pharmacotherapeutic treatment of an hs‐PDA probably does not reduce mortality in preterm infants. Low‐certainty evidence suggests that early pharmacotherapeutic treatment of hs‐PDA may lead to increased NSAID exposure in preterm infants. In addition, early pharmacotherapeutic treatment of hs‐PDA probably does not reduce CLD (moderate‐certainty evidence) and may not reduce severe IVH or NEC (low‐certainty evidence). </p> <p>We are uncertain whether very early pharmacotherapeutic treatment of hs‐PDA leads to increased NSAID exposure in preterm infants (very low‐certainty evidence). Very early treatment probably does not reduce surgical PDA ligation, severe IVH or NEC (moderate‐certainty evidence), and may not reduce CLD or neurodevelopmental impairment (low‐certainty evidence). However, low‐certainty evidence does suggest that very early treatment of hs‐PDA may reduce the duration of hospitalization in preterm infants. </p> </section> <h3 class="title" id="CD013278-sec-0145">Implications for research</h3> <section id="CD013278-sec-0145"> <p>Additional large trials adequately powered for patient‐important outcomes are required to explore if early targeted treatment of an hs‐PDA improves clinical outcomes such as mortality and neurodevelopmental impairment in preterm infants. Researchers should pay special attention to the inclusion criteria to maximize the chances of detecting a clinically meaningful signal in future trials. Extremely preterm infants born less than 28 weeks of gestational age with a large shunt volume are likely at the highest risk of PDA‐attributable morbidity (<a href="./references#CD013278-bbs2-0064" title="El-KhuffashAF , JainA , McNamaraPJ . Ligation of the patent ductus arteriosus in preterm infants: understanding the physiology. Journal of Pediatrics2013;162(6):1100-6. [DOI: 10.1016/j.jpeds.2012.12.094] [PMID: 23410600]">El‐Khuffash 2013</a>; <a href="./references#CD013278-bbs2-0079" title="MitraS , McNamaraPJ . Patent ductus arteriosus — time for a definitive trial. Clinics in Perinatology2020;47(3):617-39. [DOI: 10.1016/j.clp.2020.05.007] [PMID: 32713454]">Mitra 2020</a>). Therefore, future trials should attempt to restrict their inclusion criteria to this subgroup to avoid unnecessary exposure of more mature infants to NSAIDs where the likelihood of spontaneous PDA closure is high.Two large ongoing trials (<a href="./references#CD013278-bbs2-0047" title="ISRCTN84264977. Does selective early treatment of patent ductus arteriosus in extreme preterm infants reduce the complications and improve their long-term outcome? [Outcome after selective early closure of patent ductus ARteriosus (PDA) in extreme preterm infants: a randomised controlled trial]. www.isrctn.com/ISRCTN84264977 (first received 13 August 2010). ">ISRCTN84264977</a>; <a href="./references#CD013278-bbs2-0048" title="NCT02884219. Early treatment versus expectative management of PDA in preterm infants (BeNeDuctus) [Multi-center, randomized non-inferiority trial of early treatment versus expectative management of patent ductus arteriosus in preterm infants (BeNeDuctus Trial - Belgium Netherlands Ductus Trial)]. clinicaltrials.gov/ct2/show/NCT02884219 (first received 30 August 2020). ">NCT02884219</a>) comparing very early treatment versus conservative management of hs‐PDA in extremely preterm infants will hopefully provide further evidence on very early treatment of hs‐PDA in this gestational age group. </p> <p>The current review essentially compares early (or very early) treatment versus early conservative management. Given the high rate of open‐label treatment in the expectant management group, the current review was unable to explore if true conservative management without any exposure to NSAIDs during the hospital stay is as effective as early pharmacological treatment. If researchers attempt to answer the question whether PDA treatment truly alters clinically meaningful endpoints in preterm infants at the highest risk of PDA‐attributable morbidity, then any form of open‐label treatment in the control arm during hospital stay should be disallowed in future trials. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013278-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013278-sec-0008"></div> <div class="table" id="CD013278-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Early treatment compared to expectant management for preterm infants</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Early treatment compared to expectant management for preterm infants</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> preterm infants<br/><b>Setting:</b> Neonatal Intensive Care Unit<br/><b>Intervention:</b> early treatment (treatment of a hemodynamically significant PDA by seven days of age)<br/><b>Comparison:</b> expectant management (no treatment of a hemodynamically significant PDA in the first seven days after birth) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Expectant Management</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Early Treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality during hospital stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.46 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>500<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1,000<br/>(50 to 151) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of infants requiring surgical PDA ligation or transcatheter occlusion</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/>(0.65 to 1.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>432<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>156 per 1,000<br/>(94 to 261) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of infants receiving any pharmacotherapy for a hemodynamically significant PDA </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.30<br/>(1.86 to 2.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>232<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4 5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>989 per 1,000<br/>(799 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chronic lung disease</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/>(0.62 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>339<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>263 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1,000<br/>(163 to 339) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Severe Intraventricular hemorrhage (grades III and IV)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.32 to 2.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>171<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1,000<br/>(30 to 206) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Necrotizing enterocolitis (NEC; stage 2 or greater)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.34<br/>(0.86 to 6.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>473<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1,000<br/>(25 to 185) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> The CI included appreciable benefit and harm, therefore the certainty of evidence was rated down by one level for imprecision. </p> <p><sup>2</sup> &gt; 50% of meta‐analytic weight to studies with high or unclear risk of bias in one of sequence generation, allocation concealment, or blinding. Therefore, the certainty of evidence was rated by one level for risk of bias. </p> <p><sup>3</sup> I<sup>2</sup> value of 59% suggests there is moderate to substantial heterogeneity that cannot be explained by subgroup differences (test for subgroup differences P = 0.59). Therefore, the certainty of evidence was rated down by one level for inconsistency. </p> <p><sup>4</sup> There was high risk of bias for blinding in one study and low risk of bias across multiple domains for one study. </p> <p><sup>5</sup> Did not meet the optimal information size for detecting a 25% difference in benefit or harm (assuming a two‐sided alpha of 0.05 with 80% power). Therefore, the certainty of evidence was rated down by one level for imprecision. </p> <p><sup>6</sup> As there were few events from two small‐sample RCTs and the CI included appreciable benefit and harm, the certainty of evidence was rated down by two levels for imprecision. </p> <p><sup>7</sup> The CI included appreciable benefit favoring expectant management but crossed the threshold for no difference. Therefore, the certainty of evidence was rated down by one level for imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013278-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Very early treatment compared to expectant management for preterm infants</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Very early treatment compared to expectant management for preterm infants</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> preterm infants<br/><b>Setting:</b> Neonatal Intensive Care Unit<br/><b>Intervention:</b> very early treatment (treatment of a hemodynamically significant PDA by 72 hours of age)<br/><b>Comparison:</b> expectant management (no treatment of a hemodynamically significant PDA in the first 72 hours after birth) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Expectant Management</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Very early treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality during hospital stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.58 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>384<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1,000<br/>(98 to 258) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of infants requiring surgical PDA ligation or transcatheter occlusion</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/>(0.36 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>293<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1,000<br/>(22 to 130) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of infants receiving any pharmacotherapy for a hemodynamically significant PDA </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.64<br/>(1.31 to 2.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>156<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>329 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>540 per 1,000<br/>(431 to 675) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chronic lung disease</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.63 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>384<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4 5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>378 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313 per 1,000<br/>(238 to 408) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Severe Intraventricular hemorrhage (grades III and IV)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.64<br/>(0.21 to 1.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>240<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1,000<br/>(14 to 128) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Necrotizing enterocolitis (NEC; stage 2 or greater)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/>(0.53 to 2.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>332<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1,000<br/>(44 to 183) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 5.35 lower<br/>(9.23 lower to 1.47 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>6 7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurodevelopmental outcomes (moderate/severe cognitive delay at 18 to 24 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.27<br/>(0.03 to 2.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>79<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1,000<br/>(3 to 225) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurodevelopmental outcomes (moderate/severe motor delay at 18 to 24 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54<br/>(0.05 to 5.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>79<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1,000<br/>(2 to 279) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurodevelopmental outcomes (moderate/severe language delay at 18 to 24 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54<br/>(0.10 to 2.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>79<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1,000<br/>(10 to 271) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> The CI included appreciable benefit and harm, therefore, the certainty of evidence was rated down by one level for imprecision. </p> <p><sup>2</sup> &gt; 50% of meta‐analytic weight from studies with high risk of bias in blinding personnel and outcome assessors </p> <p><sup>3</sup> I<sup>2</sup> value of 90% suggesting substantial heterogeneity that could not be explained by subgroup differences. Therefore, the certainty of evidence was rated down by two levels for inconsistency. </p> <p><sup>4</sup> I<sup>2</sup> value of 48% suggested there was moderate heterogeneity which is partly explained by subgroup differences (test for subgroup differences, P = 0.04). The certainty of evidence was therefore rated down by one level. </p> <p><sup>5</sup> The CI included appreciable benefit favoring very early treatment but crossed the threshold for no difference. Therefore, the certainty of evidence was rated down by one level. </p> <p><sup>6</sup> I<sup>2</sup> value of 57% suggested there was moderate to serious heterogeneity which is likely explained by subgroup differences. There was minimal overlap of CIs between the ibuprofen only subgroup vs the indomethacin/ibuprofen subgroup. The certainty of evidence was therefore rated down by one level. </p> <p><sup>7</sup> The CI includes benefit that may not be clinically meaningful (1.5 days reduction in hospitalization) as well as benefit that may substantially meaningful (9 days reduction in hospitalization). Therefore the certainty of evidence was rated down by one level for imprecision </p> <p><sup>8</sup> As there were few events in a small sample single RCT and the CI included appreciable benefit and harm, the certainty of evidence was rated down by two levels for imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013278-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013278-sec-0009"></div> <section id="CD013278-sec-0010"> <h3 class="title" id="CD013278-sec-0010">Description of the condition</h3> <p>The ductus arteriosus is a blood vessel that connects the two major arteries coming out of the heart (i.e. the aorta from the left ventricle and the pulmonary artery from the right ventricle), which plays an important role in maintaining fetal circulation (<a href="./references#CD013278-bbs2-0067" title="GournayV . The ductus arteriosus: physiology, regulation, and functional and congenital anomalies. Archives of Cardiovascular Diseases2011;104(11):578-85. [DOI: 10.1016/j.acvd.2010.06.006] [PMID: 22117910]">Gournay 2011</a>). Following birth with the initiation of breathing and separation of the low‐resistance placenta, closure of the ductus arteriosus begins and functional closure continues over the next 24 to 72 hours (<a href="./references#CD013278-bbs2-0053" title="BenitzWE , Committee on Fetus and Newborn, American Academy of Pediatrics. Patent ductus arteriosus in preterm infants. Pediatrics2016;137(1):e20153730. [DOI: 10.1542/peds.2015-3730] [EMBASE: 26672023]">Benitz 2016</a>). In preterm infants, the closure is often delayed leading to the ductus arteriosus remaining patent beyond the first few days of life. In healthy preterm neonates of more than 30 weeks' gestation, this patent ductus arteriosus (PDA) closes by day four in 90%, and by day seven in 98% of infants (<a href="./references#CD013278-bbs2-0056" title="ClymanRI , CoutoJ , MurphyGM . Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?Seminars in Perinatology2012;36(2):123-9. [DOI: 10.1053/j.semperi.2011.09.022] [PMID: 22414883]">Clyman 2012</a>). In extremely preterm infants born at less than 24 weeks of gestation, the spontaneous PDA closure rates are only about 8% by day four, and 13% by day seven (<a href="./references#CD013278-bbs2-0056" title="ClymanRI , CoutoJ , MurphyGM . Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?Seminars in Perinatology2012;36(2):123-9. [DOI: 10.1053/j.semperi.2011.09.022] [PMID: 22414883]">Clyman 2012</a>). </p> <p>When the ductus arteriosus persists beyond the first few day of life, as pulmonary vascular resistance declines, blood starts flowing left‐to‐right from the aorta into the pulmonary arteries (<a href="./references#CD013278-bbs2-0053" title="BenitzWE , Committee on Fetus and Newborn, American Academy of Pediatrics. Patent ductus arteriosus in preterm infants. Pediatrics2016;137(1):e20153730. [DOI: 10.1542/peds.2015-3730] [EMBASE: 26672023]">Benitz 2016</a>). With further decreases in pulmonary vascular resistance over the first several days after birth, the proportion of aortic blood flow that is diverted into the pulmonary circulation correspondingly increases (<a href="./references#CD013278-bbs2-0053" title="BenitzWE , Committee on Fetus and Newborn, American Academy of Pediatrics. Patent ductus arteriosus in preterm infants. Pediatrics2016;137(1):e20153730. [DOI: 10.1542/peds.2015-3730] [EMBASE: 26672023]">Benitz 2016</a>). This 'ductal steal' results in excessive blood flow through the lungs, predisposing to development of pulmonary congestion, pulmonary edema, and worsening respiratory failure (<a href="./references#CD013278-bbs2-0053" title="BenitzWE , Committee on Fetus and Newborn, American Academy of Pediatrics. Patent ductus arteriosus in preterm infants. Pediatrics2016;137(1):e20153730. [DOI: 10.1542/peds.2015-3730] [EMBASE: 26672023]">Benitz 2016</a>). At the same time, diversion of blood flow from the systemic circulation leads to systemic hypoperfusion, resulting in compromised perfusion to the bowel, kidney, and brain. When a PDA is associated with clinical or echocardiographic signs of pulmonary hyperperfusion and systemic hypoperfusion, it is defined as a hemodynamically significant PDA. A persistent hemodynamically significant PDA may be associated with numerous adverse outcomes, including prolongation of assisted ventilation and higher rates of death (<a href="./references#CD013278-bbs2-0060" title="DiceJE , BhatiaJ . Patent ductus arteriosus: an overview. Journal of Pediatric Pharmacology Therapeutics2007;12(3):138-46. [DOI: 10.5863/1551-6776-12.3.138]] [PMID: 23055849]">Dice 2007</a>), bronchopulmonary dysplasia (BPD) (<a href="./references#CD013278-bbs2-0054" title="BrownER . Increased risk of bronchopulmonary dysplasia in infants with patent ductus arteriosus. Journal of Pediatrics1979;95(5 Pt 2):865-6. [DOI: 10.1016/s0022-3476(79)80454-0] [PMID: 490263]">Brown 1979</a>), necrotizing enterocolitis (NEC) (<a href="./references#CD013278-bbs2-0061" title="DollbergS , LuskyA , ReichmanB . Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. Journal of Pediatric Gastroenterology Nutrition2005;40(2):184-8. [DOI: 10.1097/00005176-200502000-00019] [PMID: 15699694]">Dollberg 2005</a>), impaired renal function (<a href="./references#CD013278-bbs2-0053" title="BenitzWE , Committee on Fetus and Newborn, American Academy of Pediatrics. Patent ductus arteriosus in preterm infants. Pediatrics2016;137(1):e20153730. [DOI: 10.1542/peds.2015-3730] [EMBASE: 26672023]">Benitz 2016</a>), intraventricular hemorrhage (IVH) (<a href="./references#CD013278-bbs2-0050" title="BallabhP . Intraventricular hemorrhage in premature infants: mechanism of disease. Pediatric Research2010;67(1):1-8. [DOI: 10.1203/PDR.0b013e3181c1b176] [PMID: 19816235]">Ballabh 2010</a>), periventricular leukomalacia (PVL) (<a href="./references#CD013278-bbs2-0055" title="ChungMY , FangPC , ChungCH , HuangCB , Ou YangMH , ChenCC . Risk factors for hemodynamically-unrelated cystic periventricular leukomalacia in very low birth weight premature infants. Journal of the Formosan Medical Association2005;104(8):571-7. [PMID: 16193178]">Chung 2005</a>), and cerebral palsy (<a href="./references#CD013278-bbs2-0062" title="DrougiaA , GiaprosV , KrallisN , TheocharisP , NikakiA , TzoufiM , et al. Incidence and risk factors for cerebral palsy in infants with perinatal problems: a 15-year review. Early Human Development2007;83(8):541-7. [DOI: 10.1016/j.earlhumdev.2006.10.004] [PMID: 17188824]">Drougia 2007</a>). However, the causal link between these associations has not been demonstrated (<a href="./references#CD013278-bbs2-0052" title="BenitzWE . Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?Journal of Perinatology2010;30(4):241-52. [DOI: 10.1038/jp.2010.3] [PMID: 20182439]">Benitz 2010</a>). </p> </section> <section id="CD013278-sec-0011"> <h3 class="title" id="CD013278-sec-0011">Description of the intervention</h3> <p>Due to the above‐mentioned potential life‐threatening complications, nonsteroidal anti‐inflammatory drugs (NSAIDs) such as indomethacin and ibuprofen are used to close a hemodynamically significant PDA. NSAIDs act by inhibition of the cyclo‐oxygenase (COX) enzyme, thereby leading to down regulation of prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), a potent relaxant of the PDA (<a href="./references#CD013278-bbs2-0077" title="MitraS , RÃƒÂ¸nnestadA , HolmstrÃƒÂ¸mH . Management of patent ductus arteriosus in preterm infants – where do we stand?Congenital Heart Disease2013;8(6):500-12. [DOI: 10.1111/chd.12143] [PMID: 24127861]">Mitra 2013</a>). Acetaminophen (paracetamol) has also emerged as a potential pharmacotherapeutic option for PDA closure (<a href="./references#CD013278-bbs2-0075" title="LeJ , GalesMA , GalesBJ . Acetaminophen for patent ductus arteriosus. Annals of Pharmacotherapy2015;49(2):241-6. [DOI: 10.1177/1060028014557564] [PMID: 25352038]">Le 2015</a>). Acetaminophen is postulated to exert its action through inhibition of the peroxidase enzyme thereby leading to down regulation of PGE<sub>2</sub> production (<a href="./references#CD013278-bbs2-0069" title="GrÃƒÂ¨enK , DrvotaV , VesterqvistO . Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). Prostaglandins1989;37(3):311-5. [DOI: 10.1016/0090-6980(89)90001-4] [PMID: 2664901]">GrÃƒÂ¨en 1989</a>). Use of indomethacin in preterm infants has been associated with transient or permanent derangement of renal function (<a href="./references#CD013278-bbs2-0090" title="SeyberthHW , RascherW , HackenthalR , WilleL . Effect of prolonged indomethacin therapy on renal function and selected vasoactive hormones in very low birth weight infants with symptomatic ductus arteriosus. Journal of Pediatrics1983;103(6):979-84. [DOI: 10.1016/s0022-3476(83)80736-7] [PMID: 6358443]">Seyberth 1983</a>), NEC (<a href="./references#CD013278-bbs2-0057" title="CoombsRC , MorganME , DurbinGM , BoothIW , McNeishAS . Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin. Archives of Disease in Childhood1990;65(10):1067-71. [PMID: 10.1136/adc.66.10.1261] [PMID: 1953019]">Coombs 1990</a>), gastrointestinal hemorrhage or perforation (<a href="./references#CD013278-bbs2-0095" title="WolfWM , SnoverDC , LeonardAS . Localized intestinal perforation following intravenous indomethacin in premature infants. Journal of Pediatric Surgery1989;24(4):409-10. [DOI: 10.1016/s0022-3468(89)80284-2] [PMID: 2732888]">Wolf 1989</a>), alteration of platelet function (<a href="./references#CD013278-bbs2-0066" title="FriedmanWF , HirschklauMJ , PrintzMP , PitlickPT , KirkpatrickSE . Pharmacologic closure of patent ductus arteriosus in the premature infant. New England Journal of Medicine1976;295(10):526-9. [DOI: 10.1056/NEJM197609022951003] [PMID: 820994]">Friedman 1976</a>), and impairment of cerebral blood flow/cerebral blood flow velocity (<a href="./references#CD013278-bbs2-0081" title="OhlssonA , BottuJ , GovanJ , RyanML , FongK , MyhrT . Effect of indomethacin on cerebral blood flow velocities in very low birth weight neonates with a patent ductus arteriosus. Developmental Pharmacology Therapeutics1993;20(1-2):100–6. [DOI: 10.1159/000457546] [PMID: 7924757]">Ohlsson 1993</a>). Ibuprofen appears to be associated with a lower risk of NEC and transient renal insufficiency as compared to indomethacin (<a href="./references#CD013278-bbs2-0083" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2020, Issue 2. Art. No: CD003481. [DOI: 10.1002/14651858.CD003481.pub8]">Ohlsson 2020b</a>). Acetaminophen has no short‐term adverse effects. However, there are limited data on the long‐term neurodevelopmental effects of acetaminophen in preterm infants (<a href="./references#CD013278-bbs2-0082" title="OhlssonA , ShahPS . Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database of Systematic Reviews2020, Issue 1. Art. No: CD010061. [DOI: 10.1002/14651858.CD010061.pub4]">Ohlsson 2020a</a>). There is considerable variation in the timing of treatment where some neonatologists choose to treat a hemodynamically significant PDA early in the first few days of life to mitigate the adverse effects of persistent left–right shunting through the ductus, while some neonatologists choose to delay treatment awaiting spontaneous closure of the PDA. In this review, we define early treatment of a hemodynamically significant PDA as intention‐to‐treat the PDA using a pharmacotherapeutic agent within the first seven days of birth, and very early treatment of a hemodynamically significant PDA by 72 hours of age. </p> <p>We define expectant management of the PDA as intention‐to‐manage a clinically or echocardiographically diagnosed (or both) hemodynamically significant PDA without pharmacological treatment within the time period defined as early treatment for the respective clinical trial. Expectant management could include non‐pharmacological interventions such as fluid restriction or modification of parameters on mechanical ventilation. </p> </section> <section id="CD013278-sec-0012"> <h3 class="title" id="CD013278-sec-0012">How the intervention might work</h3> <p>NSAIDs and acetaminophen are effective in closing a PDA compared to placebo (<a href="./references#CD013278-bbs2-0078" title="MitraS , FlorezID , TamayoME , MbuagbawL , VanniyasingamT , VeronikiAA , et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA2018;319(12):1221-38. [DOI: 10.1001/jama.2018.1896] [PMID: 29584842]">Mitra 2018</a>). Ibuprofen appears as effective as indomethacin in closing a PDA while reducing the risk of NEC and transient renal insufficiency (<a href="./references#CD013278-bbs2-0083" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2020, Issue 2. Art. No: CD003481. [DOI: 10.1002/14651858.CD003481.pub8]">Ohlsson 2020b</a>). There is moderate‐quality evidence to suggest that acetaminophen is as effective as ibuprofen and low‐quality evidence to suggest that acetaminophen is as effective as indomethacin in closing a PDA (<a href="./references#CD013278-bbs2-0082" title="OhlssonA , ShahPS . Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database of Systematic Reviews2020, Issue 1. Art. No: CD010061. [DOI: 10.1002/14651858.CD010061.pub4]">Ohlsson 2020a</a>). However, there is an increasing concern that infants who require pharmacotherapy for a hemodynamically significant PDA may not respond to the standard treatment doses of NSAIDs if they are treated beyond the first 72 hours of life due to altered pharmacokinetics of the medications. To achieve optimal concentrations of ibuprofen for successful PDA closure, irrespective of gestational age, three doses of 10 mg/kg, 5 mg/kg, and 5 mg/kg are required at 24‐hour intervals for neonates younger than 70 hours; 14 mg/kg, 7 mg/kg, and 7 mg/kg for neonates between 70 and 108 hours; and 18 mg/kg, 9 mg/kg, and 9 mg/kg for neonates between 108 and 180 hours of life (<a href="./references#CD013278-bbs2-0072" title="HirtD , Van OvermeireB , TreluyerJM , LanghendriesJP , MarguglioA , EisingerMJ , et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. British Journal of Clinical Pharmacology2008;65(5):629-36. [DOI: 10.1111/j.1365-2125.2008.03118.x] [PMID: 18307541]">Hirt 2008</a>). Therefore, timely and effective treatment within the first few days of life may prevent potential complications arising from a persistent hemodynamically significant PDA. </p> </section> <section id="CD013278-sec-0013"> <h3 class="title" id="CD013278-sec-0013">Why it is important to do this review</h3> <p>Controversy exists on timing of PDA treatment or whether the PDA should be actively treated at all in preterm infants. Spontaneous closure of PDA occurs in 34% of infants with birth weight less than 1000 g and in 67% of infants with birth weight between 1000 g and1500 g in the first seven days of life (<a href="./references#CD013278-bbs2-0056" title="ClymanRI , CoutoJ , MurphyGM . Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?Seminars in Perinatology2012;36(2):123-9. [DOI: 10.1053/j.semperi.2011.09.022] [PMID: 22414883]">Clyman 2012</a>). Therefore, expectant treatment of the PDA in the first seven days after birth may not be associated with adverse clinical outcomes in a significant proportion of preterm infants. Moreover, there is little evidence to support successful closing of the PDA leading to changes in clinical outcomes in preterm infants. One Bayesian network meta‐analysis, exploring pharmacotherapeutic treatment options for a hemodynamically significant PDA, found that placebo or no treatment did not significantly alter clinical outcomes such as mortality, NEC, or IVH, which suggests that expectant management of the PDA could also be an equally viable management option (<a href="./references#CD013278-bbs2-0078" title="MitraS , FlorezID , TamayoME , MbuagbawL , VanniyasingamT , VeronikiAA , et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA2018;319(12):1221-38. [DOI: 10.1001/jama.2018.1896] [PMID: 29584842]">Mitra 2018</a>). However, there were too few data on timing of treatment in the included studies to draw a definite conclusion from the network meta‐regression analysis. One Cochrane Review explored early versus expectant management as a secondary outcome and included one randomized controlled trial (RCT) that defined early treatment as any treatment prior to 14 days of age (<a href="./references#CD013278-bbs2-0083" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2020, Issue 2. Art. No: CD003481. [DOI: 10.1002/14651858.CD003481.pub8]">Ohlsson 2020b</a>). There are no Cochrane Reviews that explore expectant versus early management of a hemodynamically significant PDA. Currently, there are two large, multicenter, RCTs underway that explore the proposed research question: the BeNeDuctus Trial (<b>Be</b> lgium <b>Ne</b> therlands <b>Ductus</b> Trial; <a href="./references#CD013278-bbs2-0048" title="NCT02884219. Early treatment versus expectative management of PDA in preterm infants (BeNeDuctus) [Multi-center, randomized non-inferiority trial of early treatment versus expectative management of patent ductus arteriosus in preterm infants (BeNeDuctus Trial - Belgium Netherlands Ductus Trial)]. clinicaltrials.gov/ct2/show/NCT02884219 (first received 30 August 2020). ">NCT02884219</a>) and the <a href="http://www.isrctn.com/ISRCTN84264977" target="_blank">Baby-OSCAR Trial</a> (<b>O</b> utcome after <b>S</b> elective early treatment for <b>C</b> losure of patent ductus <b>AR</b>teriosus in pre‐term babies; <a href="./references#CD013278-bbs2-0047" title="ISRCTN84264977. Does selective early treatment of patent ductus arteriosus in extreme preterm infants reduce the complications and improve their long-term outcome? [Outcome after selective early closure of patent ductus ARteriosus (PDA) in extreme preterm infants: a randomised controlled trial]. www.isrctn.com/ISRCTN84264977 (first received 13 August 2010). ">ISRCTN84264977</a>). Therefore, a systematic review according to Cochrane methodology is justified as new trials have been identified. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013278-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013278-sec-0014"></div> <p>To assess the effectiveness and safety of early treatment strategies versus expectant management for a hemodynamically significant patent ductus arteriosus (PDA) in reducing mortality and morbidity in preterm infants. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013278-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013278-sec-0015"></div> <section id="CD013278-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013278-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included published and unpublished RCTs, quasi‐RCTs, and cluster‐RCTs comparing early treatment versus expectant management of hemodynamically significant PDA for preterm infants. Both superiority trials and non‐inferiority trials were eligible for inclusion. </p> </section> <section id="CD013278-sec-0018"> <h4 class="title">Types of participants</h4> <p>Preterm (gestational age less than 37 weeks at birth) or low birth weight infants (less than 2500 grams) with a hemodynamically significant PDA diagnosed clinically or via echocardiography (or both) in the first seven days of life. </p> <p>A hemodynamically significant PDA was defined clinically by the presence of a precordial murmur along with one or more of the following signs: hyperdynamic precordial impulse, tachycardia, bounding pulses, widened pulse pressure, worsening respiratory status, hypotension, or cardiac failure. </p> <p>A hemodynamically significant PDA was defined echocardiographically by a moderate‐to‐large transductal diameter (PDA diameter greater than 1.5 mm with or without unrestrictive pulsatile flow, i.e. maximum systolic shunt velocity less than 2 m/second) with or without evidence of pulmonary over circulation (left atrium to aortic root ratio greater than 1.5 OR isovolumetric relaxation time less than 55 m seconds OR E:A ratio of 1.0 or greater or left ventricular output greater than 300 mL/kg/minute OR diastolic disturbance in the main pulmonary artery) with or without evidence of systemic hypoperfusion (absent/reversed diastolic flow in the postductal descending aorta or celiac trunk or middle cerebral artery) (<a href="./references#CD013278-bbs2-0064" title="El-KhuffashAF , JainA , McNamaraPJ . Ligation of the patent ductus arteriosus in preterm infants: understanding the physiology. Journal of Pediatrics2013;162(6):1100-6. [DOI: 10.1016/j.jpeds.2012.12.094] [PMID: 23410600]">El‐Khuffash 2013</a>); or used a scoring system that incorporated one or more of the echocardiographic measures mentioned above (<a href="./references#CD013278-bbs2-0065" title="El-KhuffashA , JamesAT , CorcoranJD , DickerP , FranklinO , ElsayedYN , et al. A patent ductus arteriosus severity score predicts chronic lung disease or death before discharge. Journal of Pediatrics2015;167(6):1354-61.e2. [DOI: 10.1016/j.jpeds.2015.09.028]">El‐Khuffash 2015</a>). </p> </section> <section id="CD013278-sec-0019"> <h4 class="title">Types of interventions</h4> <p>The interventions included early pharmacological treatment and expectant management for a hemodynamically significant PDA diagnosed clinically or via echocardiography (or both). </p> <section id="CD013278-sec-0020"> <h5 class="title">Early pharmacological treatment</h5> <p>Early pharmacological treatment included 'early treatment' defined as intention‐to‐treat a hemodynamically significant PDA within the first seven days of birth, and 'very early treatment' defined as intention‐to‐treat a hemodynamically significant PDA within the first 72 hours of life. The pharmacological treatments included indomethacin, ibuprofen, and acetaminophen. There were no restrictions on dose, route, or duration of treatment. </p> </section> <section id="CD013278-sec-0021"> <h5 class="title">Expectant management</h5> <p>Expectant management was defined as intention‐to‐manage a clinically or echocardiographically (or both) diagnosed hemodynamically significant PDA without treatment within the time period defined as early treatment for the respective clinical trial. Beyond the defined 'early treatment' period, expectant management included no treatment, use of the same pharmacotherapeutic agent (i.e. same dose, route, and duration) as in the early treatment arm or surgical intervention for PDA closure. </p> </section> <section id="CD013278-sec-0022"> <h5 class="title">Planned comparisons</h5> <p>The planned comparisons included the following:</p> <p> <ol id="CD013278-list-0001"> <li> <p>early treatment (treatment of a hemodynamically significant PDA by seven days of age) versus expectant management (no treatment of a hemodynamically significant PDA in the first seven days after birth); </p> </li> <li> <p>very early treatment (treatment of a hemodynamically significant PDA by 72 hours of age) versus expectant management (no treatment of a hemodynamically significant PDA in the first 72 hours after birth); </p> </li> <li> <p>very early treatment (treatment of a hemodynamically significant PDA by 72 hours of age) versus early treatment (treatment of a hemodynamically significant PDA by seven days of age). </p> </li> </ol> </p> </section> </section> <section id="CD013278-sec-0023"> <h4 class="title">Types of outcome measures</h4> <section id="CD013278-sec-0024"> <h5 class="title">Primary outcomes</h5> <p>Outcomes were selected based on their importance for decision‐making and included:</p> <p> <ol id="CD013278-list-0002"> <li> <p>All‐cause mortality during hospital stay.</p> </li> </ol> </p> </section> <section id="CD013278-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013278-list-0003"> <li> <p>Proportion of infants requiring surgical PDA ligation or transcatheter occlusion.</p> </li> <li> <p>Proportion of infants receiving any pharmacotherapy for a hemodynamically significant PDA (defined as any receipt of pharmacotherapy for a hemodynamically significant PDA any time during hospital stay). </p> </li> <li> <p>Proportion of infants receiving repeat courses of pharmacotherapy (repeated COX inhibitor or acetaminophen dosing, or both) for a persistent hemodynamically significant PDA. </p> </li> <li> <p>Proportion of infants receiving rescue medical treatment (COX inhibitor or acetaminophen dosing, or both) for a hemodynamically significant PDA . </p> </li> <li> <p>Chronic lung disease (CLD; defined as oxygen requirement at 36 weeks' postmenstrual age) (<a href="./references#CD013278-bbs2-0063" title="EhrenkranzRA , WalshMC , VohrBR , JobeAH , WrightLL , FanaroffAA , et al, National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics2005;116(6):1353-60. [DOI: 10.1542/peds.2005-0249] [PMID: 16322158]">Ehrenkranz 2005</a>). </p> </li> <li> <p>Duration of ventilator support (days).</p> </li> <li> <p>Duration of need for supplementary oxygen (days).</p> </li> <li> <p>Postnatal corticosteroid use for CLD any time during hospital stay.</p> </li> <li> <p>Pneumothorax.</p> </li> <li> <p>Pulmonary hemorrhage.</p> </li> <li> <p>Pulmonary hypertension (defined as hypoxemia refractory to oxygen therapy or to lung recruitment strategies (partial pressure of oxygen in arterial blood (PaO<sub>2</sub>) less than 55 mmHg despite fraction of inspired oxygen (FiO<sub>2</sub>) of 1.0) associated with a preductal‐to‐postductal oxygen gradient greater than 20 mmHg) (<a href="./references#CD013278-bbs2-0086" title="Roberts JD Jr, FinemanJR , Morin FC 3rd, ShaulPW , RimarS , SchreiberMD , et al, Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. New England Journal of Medicine1997;336(9):605-10. [DOI: 10.1056/NEJM199702273360902] [PMID: 9032045]">Roberts 1997</a>; <a href="./references#CD013278-bbs2-0094" title="Walsh-SukysMC , TysonJE , WrightLL , BauerCR , KoronesSB , StevensonDK , et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics2000;105(1 Pt 1):14-20. [DOI: 10.1542/peds.105.1.14] [PMID: 10617698]">Walsh‐Sukys 2000</a>). </p> </li> <li> <p>Intraventricular hemorrhage (IVH) (grades I to IV) (<a href="./references#CD013278-bbs2-0084" title="PapileLA , BursteinJ , BursteinR , KofflerH . Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics1978;92(4):529-34. [DOI: 10.1016/s0022-3476(78)80282-0] [PMID: 305471]">Papile 1978</a>). </p> </li> <li> <p>Severe IVH (grades III and IV).</p> </li> <li> <p>Periventricular leukomalacia (PVL; any grade) (<a href="./references#CD013278-bbs2-0059" title="De VriesLS , EkenP , DubowitzLM . The spectrum of leukomalacia using cranial ultrasound. Behavioural Brain Research1992;49(1):1-6. [DOI: 10.1016/s0166-4328(05)80189-5] [PMID: 1388792]">De Vries 1992</a>). </p> </li> <li> <p>Necrotizing enterocolitis (NEC; stage 2 or greater) (<a href="./references#CD013278-bbs2-0051" title="BellMJ , TernbergJL , FeiginRD , KeatingJP , MarshallR , BartonL , et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery1978;187(1):1-7. [DOI: 10.1097/00000658-197801000-00001] [PMID: 413500]">Bell 1978</a>). </p> </li> <li> <p>Gastrointestinal bleeding within seven days of the first dose of pharmacotherapy.</p> </li> <li> <p>Spontaneous intestinal perforation.</p> </li> <li> <p>Time to full enteral feeds (postnatal age at time of achieving full enteral feeds).</p> </li> <li> <p>Time to regain birth weight (days).</p> </li> <li> <p>Severe retinopathy of prematurity (ROP) (stage 3 or greater) (according to the international classification of ROP) (<a href="./references#CD013278-bbs2-0074" title="International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Archives of Ophthalmology2005;123(7):991-9. [DOI: 10.1001/archopht.123.7.991] [PMID: 16009843]">ICCROP 2005</a>). </p> </li> <li> <p>Definite sepsis (clinical symptoms and signs of sepsis and a positive bacterial culture in a specimen obtained from normally sterile fluids or tissue obtained at postmortem). </p> </li> <li> <p>Oliguria (defined as less than 1 mL/kg/hour).</p> </li> <li> <p>Duration of hospitalization (total length of hospitalization from birth to discharge home or mortality) (days). </p> </li> <li> <p>Neurodevelopmental outcome (assessed by a standardized and validated assessment tool, a child developmental specialist, or both) at any age reported (outcome data grouped at 12, 18, and 24 months, if available). </p> </li> </ol> </p> </section> </section> </section> <section id="CD013278-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013278-sec-0027"> <h4 class="title">Electronic searches</h4> <p>We initially conducted a comprehensive search including: Cochrane Central Register of Controlled Trials (CENTRAL 2019, issue 6) in the Cochrane Library; MEDLINE via PubMed (1996 to 31 May 2019); Embase via Ovid (1980 to 31 May 2019); and CINAHL via EBSCOhost (1982 to 31 May 2019) using the following search terms: patent ductus arteriosus, PDA, indomethacin, ibuprofen, paracetamol, acetaminophen, Tylenol, and applicable MeSH terms plus database‐specific limiters for RCTs and neonates. We further conducted a comprehensive updated search in October 2020 including: Cochrane Central Register of Controlled Trials (CENTRAL 2020, Issue 10) in the Cochrane Library and Ovid MEDLINE(R) and Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Daily and Versions(R) (01 January 2019 to 02 October 2020). </p> <p>We searched clinical trial registries for ongoing or recently completed trials. We searched the World Health Organization’s International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/ictrp/search/en/</a>) and the U.S. National Library of Medicine’s ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>) via Cochrane CENTRAL. Additionally, we searched the ISRCTN Registry (<a href="http://www.isrctn.com/" target="_blank">http://www.isrctn.com/</a>) for any unique trials not found through the Cochrane CENTRAL search. </p> <p>We have included the updated search strategy for each database in <a href="./appendices#CD013278-sec-0149">Appendix 1</a>. The initial search details are listed in <a href="./appendices#CD013278-sec-0153">Appendix 2</a>. We did not apply language restrictions. </p> </section> <section id="CD013278-sec-0028"> <h4 class="title">Searching other resources</h4> <p>Additionally, we identified relevant studies not identified in the primary search through a review of the reference lists of all identified articles, correspondence with experts in the field, and a search of conference proceedings for the European Society for Pediatric Research and US Pediatric Academic Societies (1990 to 2020). </p> </section> </section> <section id="CD013278-sec-0029"> <h3 class="title" id="CD013278-sec-0029">Data collection and analysis</h3> <p>We used the standard methods of Cochrane Neonatal.</p> <section id="CD013278-sec-0030"> <h4 class="title">Selection of studies</h4> <p>Three review authors (SM, AS and TD) independently screened the search results in duplicate by title and abstract for studies that potentially met the inclusion criteria. We obtained the full text of any articles that were potentially eligible, and independently performed full‐text assessments in duplicate. We resolved any disagreements through consensus. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD013278-bbs2-0080" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12. [DOI: 10.1371/journal.pmed.1000097] [PMID: 19631508]">Moher 2009</a>) (<a href="#CD013278-fig-0001">Figure 1</a>), and '<a href="./references#CD013278-sec-0176" title="">Characteristics of included studies</a>' and '<a href="./references#CD013278-sec-0177" title="">Characteristics of excluded studies</a>' table. The study selection process was conducted on the <a href="./references#CD013278-bbs2-0058" title="Veritas Health InnovationCovidence. Version accessed 15 September 2018. Melbourne, Australia: Veritas Health Innovation. Available at www.covidence.org.">Covidence</a> platform. </p> <div class="figure" id="CD013278-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD013278-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD013278-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (SM, AS and AvK) extracted, assessed, and coded all data for each study, using a standardized form developed on the <a href="./references#CD013278-bbs2-0058" title="Veritas Health InnovationCovidence. Version accessed 15 September 2018. Melbourne, Australia: Veritas Health Innovation. Available at www.covidence.org.">Covidence</a> platform. We replaced any standard error of the mean by the corresponding standard deviation. We used the formulae proposed by Hozo and colleagues, to estimate means and standard deviations (SD) from medians and ranges presented by the authors of some of the included studies (<a href="./references#CD013278-bbs2-0073" title="HozoSP , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology2005;5:13. [DOI: 10.1186/1471-2288-5-13] [PMID: 15840177]">Hozo 2005</a>). We resolved any disagreements through consensus. For each study, one review author (SM) entered the extracted data into Review Manager 5 (<a href="./references#CD013278-bbs2-0085" title="The Cochrane CollaborationReview Manager (RevMan). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>); a second review author (AS) checked data entry. All review authors assessed the protocol, analysis, and draft manuscript. We collected information regarding the method of randomization, blinding, drug intervention, and stratification for each included study. We noted the information regarding trial participants including gestational age criteria, birth weight criteria, and other inclusion or exclusion criteria. We analyzed the information on clinical outcomes of the primary and secondary outcomes. </p> </section> <section id="CD013278-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SM and AvK) independently assessed the risk of bias (low, high, or unclear) of all included trials using the Cochrane 'Risk of bias' tool (<a href="./references#CD013278-bbs2-0070" title="HigginsJP , AltmanDG , SterneJA , Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from trraining.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>), for the following domains (<a href="./references#CD013278-bbs2-0071" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook.">Higgins 2017</a>): </p> <p> <ol id="CD013278-list-0004"> <li> <p>sequence generation (selection bias);</p> </li> <li> <p>allocation concealment (selection bias);</p> </li> <li> <p>blinding of participants and personnel (performance bias);</p> </li> <li> <p>blinding of outcome assessment (detection bias);</p> </li> <li> <p>incomplete outcome data (attrition bias);</p> </li> <li> <p>selective reporting (reporting bias);</p> </li> <li> <p>any other bias.</p> </li> </ol> </p> <p>We resolved any disagreements by discussion or with a third‐party assessor. See <a href="./appendices#CD013278-sec-0158">Appendix 3</a> for a more detailed description of risk of bias for each domain. </p> </section> <section id="CD013278-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>We performed statistical analyses using Review Manager 5 (<a href="./references#CD013278-bbs2-0085" title="The Cochrane CollaborationReview Manager (RevMan). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We used risk ratios (RRs) and risk differences (RDs) for categorical variables, and mean differences (MDs) for continuous variables. We reported the 95% confidence interval (CI) on all estimates. </p> </section> <section id="CD013278-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participating infant in individually randomized trials, and we conducted intention‐to‐treat analyses. </p> <p>If included trials used cluster randomization and the analysis was adjusted for patient clustering, we extracted this effect estimate. If clustering was ignored, we conducted analyses by calculating an effective sample size for intervention and control. We used the intracluster correlation coefficient of the study if reported or a reasonable external estimate if it was not (<a href="./references#CD013278-bbs2-0071" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook.">Higgins 2017</a>). If we identified both cluster‐RCTs and individually randomized controlled trials, we only combined the results from both if there was little heterogeneity between the study designs and the interaction between the effect of the intervention and the choice of randomization unit was unlikely. </p> <p>In the event that included trials had more than two intervention groups, we combined the groups to create a single pairwise comparison as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013278-bbs2-0071" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook.">Higgins 2017</a>). </p> </section> <section id="CD013278-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the study authors to request any missing data. If this was unsuccessful, we assumed that data were missing at random and conducted analysis using the data reported by study authors (e.g. the denominator being the number randomized minus participants whose outcomes were missing). We planned to conduct a sensitivity analysis assessing the impact of including these trials. If standard deviations for continuous outcomes were missing, we first looked for summary statistics that could be used to calculate these, contacted authors when these were not available, and finally used methods outlined in Chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to impute missing standard deviations if the proportion of studies requiring imputation was small (<a href="./references#CD013278-bbs2-0071" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook.">Higgins 2017</a>). We planned to conduct sensitivity analysis to assess the impact of including any imputed values. </p> </section> <section id="CD013278-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>Prior to synthesis, we assessed all studies for differences that may give rise to heterogeneity. These potential effect modifiers included: differences in study quality, participants, timing of the intervention, pharmacotherapeutic regimens, and outcome assessments. We additionally examined evidence of heterogeneity visually by inspecting the forest plots, and quantitatively using the I<sup>2</sup> statistic. We assessed the degree of heterogeneity as: </p> <p> <ol id="CD013278-list-0005"> <li> <p>less than 25%: no heterogeneity;</p> </li> <li> <p>25% to 49%: low heterogeneity;</p> </li> <li> <p>50% to 74%: moderate heterogeneity; or</p> </li> <li> <p>greater than 75%: substantial heterogeneity.</p> </li> </ol> </p> </section> <section id="CD013278-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess possible publication bias through contour‐enhanced funnel plots if there were 10 or more clinical trials for a particular comparison (<a href="./references#CD013278-bbs2-0071" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook.">Higgins 2017</a>). In addition, we evaluated whether results of published posters and available dissertations were subsequently published as full‐length manuscripts. We identified records in trial registries that had been terminated, listed as complete, or should have been feasibly completed given last updated status with regard to availability of results or subsequent publication. For preregistered trials or those with published protocols, we assessed the presence of reporting bias through comparison of their preplanned primary and secondary outcomes and analysis methods against those reported and used in the published report. </p> </section> <section id="CD013278-sec-0038"> <h4 class="title">Data synthesis</h4> <p>When considered appropriate, we used Review Manager 5 to conduct meta‐analyses (<a href="./references#CD013278-bbs2-0085" title="The Cochrane CollaborationReview Manager (RevMan). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>). For categorical outcomes, we calculated the typical estimates of RR and RD, each with its 95% CI; and for continuous outcomes, we determined the MD with its 95% CI. All models were analyzed using fixed‐effect models. If meta‐analysis was considered to be inappropriate, we analyzed and interpreted individual trials separately. </p> </section> <section id="CD013278-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD013278-sec-0040"> <h5 class="title">Subgroup analyses</h5> <p>If the information was available, we planned to conduct the following subgroup analyses for the primary outcome. </p> <p> <ol id="CD013278-list-0006"> <li> <p>Gestational age (less than 28 weeks, 28 to 32 weeks, 33 to 37 weeks).</p> </li> <li> <p>Birth weight (less than 1000 g, 1000 g to 1500 g, 1501 g to 2500 g).</p> </li> <li> <p>Method used to diagnose a hemodynamically significant PDA (by echocardiographic criteria or only by clinical criteria). </p> </li> <li> <p>Degree of hemodynamic significance of the PDA (based on echocardiographic criteria):</p> <ol id="CD013278-list-0007"> <li> <p>moderately hemodynamically significant PDA (defined by a moderate transductal diameter (PDA diameter 1.5 mm to 3 mm with or without unrestrictive pulsatile flow, i.e. maximum systolic shunt velocity less than 2 m/second) with or without evidence of pulmonary over circulation (left atrium‐to‐aortic root ratio 1.5 to 2.0 OR isovolumetric relaxation time 45 milliseconds to 55 milliseconds or E:A ratio 1.0 or left ventricular output 300 mL/kg/minute to 400 mL/kg/minute or main pulmonary artery diastolic velocity 0.3 m/second to 0.5 m/second) with or without evidence of systemic hypoperfusion (absent diastolic flow in the postductal descending aorta or celiac trunk or middle cerebral artery); or </p> </li> <li> <p>large hemodynamically significant PDA (defined by a large transductal diameter (PDA diameter greater than 3 mm with or without unrestrictive pulsatile flow, i.e. maximum systolic shunt velocity less than 2 m/second) with or without evidence of pulmonary over circulation (left atrium‐to‐aortic root ratio greater than 2.0 or isovolumetric relaxation time less than 45 milliseconds or E:A ratio greater than 1.0 or left ventricular output greater than 400 mL/kg/minute or main pulmonary artery diastolic velocity greater than 0.5 m/second) with or without evidence of systemic hypoperfusion (reversed diastolic flow in the postductal descending aorta or celiac trunk or middle cerebral artery) (<a href="./references#CD013278-bbs2-0064" title="El-KhuffashAF , JainA , McNamaraPJ . Ligation of the patent ductus arteriosus in preterm infants: understanding the physiology. Journal of Pediatrics2013;162(6):1100-6. [DOI: 10.1016/j.jpeds.2012.12.094] [PMID: 23410600]">El‐Khuffash 2013</a>). </p> </li> </ol> </li> <li> <p>Use of prophylactic COX inhibitor therapy in the first 24 hours (yes/no).</p> </li> <li> <p>Pharmacotherapeutic agent for PDA treatment (<a href="./appendices#CD013278-sec-0166">Appendix 4</a>). </p> </li> <li> <p>Co‐interventions (fluid intake restriction, diuretic medication, optimizing hematocrit levels, optimizing platelet counts, optimizing mechanical ventilation). </p> </li> </ol> </p> </section> </section> <section id="CD013278-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses to determine whether findings were affected by including only studies of adequate methodology (low risk of bias), defined as adequate randomization and allocation concealment, blinding of intervention and measurement, and up to and including a 10% loss to follow‐up. </p> </section> <section id="CD013278-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach, as outlined in the <a href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html" target="_blank">GRADE Handbook</a> to assess the certainty of evidence for the following (clinically relevant) outcomes (<a href="./references#CD013278-bbs2-0089" title="SchÃƒÂ¼nemannH , BrożekJ , GuyattG , OxmanA , editor(s), GRADE Working Group. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">SchÃƒÂ¼nemann 2013</a>): </p> <p> <ol id="CD013278-list-0008"> <li> <p>All‐cause mortality during hospital stay.</p> </li> <li> <p>Proportion of infants requiring surgical PDA ligation or transcatheter occlusion.</p> </li> <li> <p>Proportion of infants receiving any pharmacotherapy for a hemodynamically significant PDA (defined as any receipt of pharmacotherapy for a hemodynamically significant PDA any time during hospital stay). </p> </li> <li> <p>CLD (defined as oxygen requirement at 36 weeks' postmenstrual age).</p> </li> <li> <p>Severe IVH (grades III and IV).</p> </li> <li> <p>NEC (stage 2 or greater).</p> </li> <li> <p>Duration of hospitalization (total length of hospitalization from birth to discharge home or mortality). </p> </li> <li> <p>Neurodevelopmental outcome (assessed by a standardized and validated assessment tool, a child developmental specialist, or both) at any age reported (outcome data grouped at 12, 18, and 24 months, if available). </p> </li> </ol> </p> <p>Two out of the following three review authors (SM, AS and TD) independently assessed the certainty of the evidence for each of the outcomes above. We considered evidence from RCTs as high certainty but downgraded the evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates, and presence of publication bias. We used the <a href="./references#CD013278-bbs2-0068" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 8 November 2018. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a> Guideline Development Tool to create two 'Summary of findings' tables to report the certainty of the evidence. </p> <p>The GRADE approach results in an assessment of the certainty of a body of evidence in one of four grades. </p> <p> <ol id="CD013278-list-0009"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013278-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013278-sec-0043"></div> <section id="CD013278-sec-0044"> <h3 class="title">Description of studies</h3> <p>We identified 1456 potentially relevant studies through the electronic search. We identified 48 studies of relevance through title and abstract screening followed by full‐text screening. We excluded 30 studies through full‐text screening. We further identified two studies that are awaiting classification (<a href="./references#CD013278-bbs2-0045" title="ACTRN12616001517460. Early PARacetamol (EPAR) to promote early closure of the ductus arteriosus in preterm infants. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12616001517460 (first received 2 November 2011). ">ACTRN12616001517460</a>; <a href="./references#CD013278-bbs2-0046" title="NCT01630278. Early ibuprofen treatment of patent ductus arteriosus (PDA) in premature infants (TRIOCAPI) (TRIOCAPI) [Impact of early targeted ibuprofene treatment of patent ductus arteriosus (PDA) on long term neurodevelopmental outcome in very premature infants (TRIOCAPI)]. clinicaltrials.gov/ct2/show/NCT01630278 (first received 28 June 2012). ">NCT01630278</a>), and two ongoing studies (<a href="./references#CD013278-bbs2-0047" title="ISRCTN84264977. Does selective early treatment of patent ductus arteriosus in extreme preterm infants reduce the complications and improve their long-term outcome? [Outcome after selective early closure of patent ductus ARteriosus (PDA) in extreme preterm infants: a randomised controlled trial]. www.isrctn.com/ISRCTN84264977 (first received 13 August 2010). ">ISRCTN84264977</a>, <a href="./references#CD013278-bbs2-0048" title="NCT02884219. Early treatment versus expectative management of PDA in preterm infants (BeNeDuctus) [Multi-center, randomized non-inferiority trial of early treatment versus expectative management of patent ductus arteriosus in preterm infants (BeNeDuctus Trial - Belgium Netherlands Ductus Trial)]. clinicaltrials.gov/ct2/show/NCT02884219 (first received 30 August 2020). ">NCT02884219</a>), leaving 14 studies which were included in the review. </p> <section id="CD013278-sec-0045"> <h4 class="title">Results of the search</h4> <p>The results of the updated search conducted in October 2020 are shown in <a href="#CD013278-fig-0001">Figure 1</a> (PRISMA flow diagram). </p> </section> <section id="CD013278-sec-0046"> <h4 class="title">Included studies</h4> <p>We included a total of 14 studies that enrolled 910 participants.</p> <p>The included studies compared early (seven studies) or very early (seven studies) medical treatment of PDA with expectant management. The individual study characteristics, inclusion criteria, treatment details, outcome details and author information can be found in the <a href="./references#CD013278-sec-0176" title="">Characteristics of included studies</a> table. </p> <section id="CD013278-sec-0047"> <h5 class="title">Early versus expectant management</h5> <p>Seven studies compared early treatment with expectant management of PDA (<a href="./references#CD013278-bbs2-0001" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. Journal of Maternal-Fetal and Neonatal Medicine2013;26(4):423-9. [DOI: 10.3109/14767058.2012.733775] [PMID: 23057804]">Bagnoli 2013</a>; <a href="./references#CD013278-bbs2-0005" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]">Gersony 1983</a>; <a href="./references#CD013278-bbs2-0006" title="GhanemS , MostafaM , ShafeeM . Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. Journal of the Saudi Heart Association2010;22(1):7-12. [DOI: 10.1016/j.jsha.2010.01.002] [PMID: 23960586]">Ghanem 2010</a>; <a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a>; <a href="./references#CD013278-bbs2-0010" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78-81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a>; <a href="./references#CD013278-bbs2-0014" title="Van OvermeireB , Van De BroekH , Van LaerP , WeylerJ , VanhaesebrouckP . Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. Journal of Pediatrics2001;138(2):205-11. [DOI: 10.1067/mpd.2001.110528] [PMID: 11174617]">Van Overmeire 2001</a>). All seven studies were RCTs. For the <a href="./references#CD013278-bbs2-0005" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]">Gersony 1983</a> study, data from only a subgroup of infants randomized within the first five days after birth was specifically included in the meta‐analysis. <a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a> was published as a conference abstract. </p> <p>Of these seven studies, two used intravenous ibuprofen (<a href="./references#CD013278-bbs2-0001" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. Journal of Maternal-Fetal and Neonatal Medicine2013;26(4):423-9. [DOI: 10.3109/14767058.2012.733775] [PMID: 23057804]">Bagnoli 2013</a>; <a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a>) (ibuprofen‐lysine), four used intravenous indomethacin (<a href="./references#CD013278-bbs2-0005" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]">Gersony 1983</a>; <a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a>; <a href="./references#CD013278-bbs2-0010" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78-81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013278-bbs2-0014" title="Van OvermeireB , Van De BroekH , Van LaerP , WeylerJ , VanhaesebrouckP . Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. Journal of Pediatrics2001;138(2):205-11. [DOI: 10.1067/mpd.2001.110528] [PMID: 11174617]">Van Overmeire 2001</a>), and one used oral ibuprofen (<a href="./references#CD013278-bbs2-0006" title="GhanemS , MostafaM , ShafeeM . Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. Journal of the Saudi Heart Association2010;22(1):7-12. [DOI: 10.1016/j.jsha.2010.01.002] [PMID: 23960586]">Ghanem 2010</a>). Both <a href="./references#CD013278-bbs2-0001" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. Journal of Maternal-Fetal and Neonatal Medicine2013;26(4):423-9. [DOI: 10.3109/14767058.2012.733775] [PMID: 23057804]">Bagnoli 2013</a> and <a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a> used three doses of IV ibuprofen: 10 mg/kg, followed by two 5 mg/kg doses on successive days. <a href="./references#CD013278-bbs2-0006" title="GhanemS , MostafaM , ShafeeM . Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. Journal of the Saudi Heart Association2010;22(1):7-12. [DOI: 10.1016/j.jsha.2010.01.002] [PMID: 23960586]">Ghanem 2010</a> used the same dose of ibuprofen, but via the oral route. <a href="./references#CD013278-bbs2-0010" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78-81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a> and <a href="./references#CD013278-bbs2-0014" title="Van OvermeireB , Van De BroekH , Van LaerP , WeylerJ , VanhaesebrouckP . Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. Journal of Pediatrics2001;138(2):205-11. [DOI: 10.1067/mpd.2001.110528] [PMID: 11174617]">Van Overmeire 2001</a> used three doses of indomethacin or 200 micrograms/kg on successive days, whereas <a href="./references#CD013278-bbs2-0005" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]">Gersony 1983</a> used either this dose, or 200 micrograms/kg followed by two 100 micrograms/kg doses. <a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a> used 200 micrograms/kg or 100 micrograms/kg of indomethacin on six successive days. </p> <p>‘Early treatment’ was defined in this review as medication administered prior to seven days since birth. Each study used different age entry criteria. These can be found in the table <a href="./references#CD013278-sec-0176" title="">Characteristics of included studies</a>. The infants' age ranges varied: 24 hours to 14 days (<a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a>); 48 to 96 hours (<a href="./references#CD013278-bbs2-0006" title="GhanemS , MostafaM , ShafeeM . Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. Journal of the Saudi Heart Association2010;22(1):7-12. [DOI: 10.1016/j.jsha.2010.01.002] [PMID: 23960586]">Ghanem 2010</a>); 72 to 96 hours (<a href="./references#CD013278-bbs2-0010" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78-81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>); 2 to 6 days (<a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a>); &gt; 72 hours (<a href="./references#CD013278-bbs2-0001" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. Journal of Maternal-Fetal and Neonatal Medicine2013;26(4):423-9. [DOI: 10.3109/14767058.2012.733775] [PMID: 23057804]">Bagnoli 2013</a>); &lt; 5 days (<a href="./references#CD013278-bbs2-0005" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]">Gersony 1983</a>); and 3 to 7 days (<a href="./references#CD013278-bbs2-0014" title="Van OvermeireB , Van De BroekH , Van LaerP , WeylerJ , VanhaesebrouckP . Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. Journal of Pediatrics2001;138(2):205-11. [DOI: 10.1067/mpd.2001.110528] [PMID: 11174617]">Van Overmeire 2001</a>). </p> <p>The studies varied in size between 26 participants (<a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a>), and 134 participants (<a href="./references#CD013278-bbs2-0001" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. Journal of Maternal-Fetal and Neonatal Medicine2013;26(4):423-9. [DOI: 10.3109/14767058.2012.733775] [PMID: 23057804]">Bagnoli 2013</a>). The studies were performed between 1981 (<a href="./references#CD013278-bbs2-0005" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]">Gersony 1983</a>), and 2010 (<a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a>). </p> <p>A weight cutoff for inclusion of &lt; 1750 g was used by <a href="./references#CD013278-bbs2-0005" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]">Gersony 1983</a>, &lt; 1500 g by three studies (<a href="./references#CD013278-bbs2-0001" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. Journal of Maternal-Fetal and Neonatal Medicine2013;26(4):423-9. [DOI: 10.3109/14767058.2012.733775] [PMID: 23057804]">Bagnoli 2013</a>; <a href="./references#CD013278-bbs2-0006" title="GhanemS , MostafaM , ShafeeM . Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. Journal of the Saudi Heart Association2010;22(1):7-12. [DOI: 10.1016/j.jsha.2010.01.002] [PMID: 23960586]">Ghanem 2010</a>; <a href="./references#CD013278-bbs2-0010" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78-81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>), and &lt; 1250 g by two studies (<a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a>; <a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a>). Infants of gestational age at birth &lt; 32 weeks were included by five studies (<a href="./references#CD013278-bbs2-0001" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. Journal of Maternal-Fetal and Neonatal Medicine2013;26(4):423-9. [DOI: 10.3109/14767058.2012.733775] [PMID: 23057804]">Bagnoli 2013</a>; <a href="./references#CD013278-bbs2-0006" title="GhanemS , MostafaM , ShafeeM . Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. Journal of the Saudi Heart Association2010;22(1):7-12. [DOI: 10.1016/j.jsha.2010.01.002] [PMID: 23960586]">Ghanem 2010</a>; <a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a>; <a href="./references#CD013278-bbs2-0014" title="Van OvermeireB , Van De BroekH , Van LaerP , WeylerJ , VanhaesebrouckP . Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. Journal of Pediatrics2001;138(2):205-11. [DOI: 10.1067/mpd.2001.110528] [PMID: 11174617]">Van Overmeire 2001</a>). <a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a> included only infants born &lt; 28 weeks. </p> <p>Two studies were multicenter (<a href="./references#CD013278-bbs2-0005" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]">Gersony 1983</a> ‐ 13 centers; <a href="./references#CD013278-bbs2-0014" title="Van OvermeireB , Van De BroekH , Van LaerP , WeylerJ , VanhaesebrouckP . Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. Journal of Pediatrics2001;138(2):205-11. [DOI: 10.1067/mpd.2001.110528] [PMID: 11174617]">Van Overmeire 2001</a> ‐ four centers), and the others were single‐center. Three studies were performed in the USA (<a href="./references#CD013278-bbs2-0005" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]">Gersony 1983</a>; <a href="./references#CD013278-bbs2-0010" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78-81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a>); two in Europe (<a href="./references#CD013278-bbs2-0001" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. Journal of Maternal-Fetal and Neonatal Medicine2013;26(4):423-9. [DOI: 10.3109/14767058.2012.733775] [PMID: 23057804]">Bagnoli 2013</a>; <a href="./references#CD013278-bbs2-0014" title="Van OvermeireB , Van De BroekH , Van LaerP , WeylerJ , VanhaesebrouckP . Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. Journal of Pediatrics2001;138(2):205-11. [DOI: 10.1067/mpd.2001.110528] [PMID: 11174617]">Van Overmeire 2001</a>), one in Australia (<a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a>), and one in Saudi Arabia (<a href="./references#CD013278-bbs2-0006" title="GhanemS , MostafaM , ShafeeM . Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. Journal of the Saudi Heart Association2010;22(1):7-12. [DOI: 10.1016/j.jsha.2010.01.002] [PMID: 23960586]">Ghanem 2010</a>). </p> </section> <section id="CD013278-sec-0048"> <h5 class="title">Very early versus expectant management</h5> <p>Seven studies compared very early treatment with expectant management of PDA (<a href="./references#CD013278-bbs2-0002" title="CTRI/2009/091/000041. RCT comparing indomethacin vs. no treatment for PDA on the basis of size in the first 24 hrs of life in preterm neonates between 28 to 32 weeks gestation requiring assisted ventilation. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=318&amp;EncHid=&amp;modid=&amp;compid=%27,%27318det%272010. ">CTRI/2009/091/000041</a>; <a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>; <a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a>; <a href="./references#CD013278-bbs2-0007" title="KaapaP , LanningP , KoivistoM . Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome. Acta Paediatrica Scandinavica1983;72(2):179-84. [DOI: 10.1111/j.1651-2227.1983.tb09693.x] [PMID: 6340412 ]">Kaapa 1983</a>; <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>; <a href="./references#CD013278-bbs2-0011" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Chinese Journal of Contemporary Pediatrics2012;14(7):502-5. [PMID: 22809601]">Lin 2012</a>; <a href="./references#CD013278-bbs2-0012" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>). All seven studies were RCTs. <a href="./references#CD013278-bbs2-0002" title="CTRI/2009/091/000041. RCT comparing indomethacin vs. no treatment for PDA on the basis of size in the first 24 hrs of life in preterm neonates between 28 to 32 weeks gestation requiring assisted ventilation. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=318&amp;EncHid=&amp;modid=&amp;compid=%27,%27318det%272010. ">CTRI/2009/091/000041</a> was published as a conference abstract. <a href="./references#CD013278-bbs2-0093" title="VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102.">Varghese 2016</a> is a follow‐up study of the RCT by <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>, using the same participants. </p> <p>Of these seven RCTs, four used intravenous indomethacin (<a href="./references#CD013278-bbs2-0002" title="CTRI/2009/091/000041. RCT comparing indomethacin vs. no treatment for PDA on the basis of size in the first 24 hrs of life in preterm neonates between 28 to 32 weeks gestation requiring assisted ventilation. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=318&amp;EncHid=&amp;modid=&amp;compid=%27,%27318det%272010. ">CTRI/2009/091/000041</a>; <a href="./references#CD013278-bbs2-0007" title="KaapaP , LanningP , KoivistoM . Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome. Acta Paediatrica Scandinavica1983;72(2):179-84. [DOI: 10.1111/j.1651-2227.1983.tb09693.x] [PMID: 6340412 ]">Kaapa 1983</a>; <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>; <a href="./references#CD013278-bbs2-0012" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>), one used intravenous ibuprofen (<a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a>), one used intravenous ibuprofen‐lysine or indomethacin (<a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>), and one used oral ibuprofen (<a href="./references#CD013278-bbs2-0011" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Chinese Journal of Contemporary Pediatrics2012;14(7):502-5. [PMID: 22809601]">Lin 2012</a>). The doses of intravenous indomethacin used were 200 micrograms/kg followed by two 100 micrograms/kg doses 24 hours apart in three RCTs (<a href="./references#CD013278-bbs2-0002" title="CTRI/2009/091/000041. RCT comparing indomethacin vs. no treatment for PDA on the basis of size in the first 24 hrs of life in preterm neonates between 28 to 32 weeks gestation requiring assisted ventilation. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=318&amp;EncHid=&amp;modid=&amp;compid=%27,%27318det%272010. ">CTRI/2009/091/000041</a>; <a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>; <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>), 200 micrograms/kg repeated daily as necessary until ductal closure in one RCT (<a href="./references#CD013278-bbs2-0007" title="KaapaP , LanningP , KoivistoM . Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome. Acta Paediatrica Scandinavica1983;72(2):179-84. [DOI: 10.1111/j.1651-2227.1983.tb09693.x] [PMID: 6340412 ]">Kaapa 1983</a>), and 200 micrograms/kg repeated daily up to three times in one RCT (<a href="./references#CD013278-bbs2-0012" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>). The doses of intravenous ibuprofen used were 10 mg/kg, followed by two 5 mg/kg doses 24 hours apart by <a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a> and <a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>. The same dosing regimen was used via the oral route by <a href="./references#CD013278-bbs2-0011" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Chinese Journal of Contemporary Pediatrics2012;14(7):502-5. [PMID: 22809601]">Lin 2012</a>. </p> <p>‘Very early’ treatment was defined in this review as medication administered within 72 hours of birth. However, between the studies there was some variation. For full inclusion criteria, please see the <a href="./references#CD013278-sec-0176" title="">Characteristics of included studies</a>. </p> <p>Infants were included if they weighed &lt; 1500 g in one RCT (<a href="./references#CD013278-bbs2-0011" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Chinese Journal of Contemporary Pediatrics2012;14(7):502-5. [PMID: 22809601]">Lin 2012</a>) and &lt; 1350 g in a further RCT (<a href="./references#CD013278-bbs2-0012" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>). Infants were included if born at &lt; 29 weeks of gestation in three RCTs (<a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>; <a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a>; <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>). Infants born at &lt; 32 weeks were included by <a href="./references#CD013278-bbs2-0011" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Chinese Journal of Contemporary Pediatrics2012;14(7):502-5. [PMID: 22809601]">Lin 2012</a>, whereas <a href="./references#CD013278-bbs2-0002" title="CTRI/2009/091/000041. RCT comparing indomethacin vs. no treatment for PDA on the basis of size in the first 24 hrs of life in preterm neonates between 28 to 32 weeks gestation requiring assisted ventilation. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=318&amp;EncHid=&amp;modid=&amp;compid=%27,%27318det%272010. ">CTRI/2009/091/000041</a> had gestational range of 28 to 32 weeks. <a href="./references#CD013278-bbs2-0007" title="KaapaP , LanningP , KoivistoM . Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome. Acta Paediatrica Scandinavica1983;72(2):179-84. [DOI: 10.1111/j.1651-2227.1983.tb09693.x] [PMID: 6340412 ]">Kaapa 1983</a> included all infants born preterm. </p> <p>Included RCTs were performed between 1981 (<a href="./references#CD013278-bbs2-0012" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>), and 2020 (<a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a>). The RCTs varied in size between 24 participants (<a href="./references#CD013278-bbs2-0012" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>), and 92 participants (<a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>). Two RCTs were multicenter (<a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a> ‐ three centers; <a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a> ‐ two centers) and the rest were single‐center. Two RCTs were performed in Australia (<a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>; <a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>); two in Europe (<a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a>; <a href="./references#CD013278-bbs2-0007" title="KaapaP , LanningP , KoivistoM . Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome. Acta Paediatrica Scandinavica1983;72(2):179-84. [DOI: 10.1111/j.1651-2227.1983.tb09693.x] [PMID: 6340412 ]">Kaapa 1983</a>); one in India (<a href="./references#CD013278-bbs2-0002" title="CTRI/2009/091/000041. RCT comparing indomethacin vs. no treatment for PDA on the basis of size in the first 24 hrs of life in preterm neonates between 28 to 32 weeks gestation requiring assisted ventilation. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=318&amp;EncHid=&amp;modid=&amp;compid=%27,%27318det%272010. ">CTRI/2009/091/000041</a>); one in China (<a href="./references#CD013278-bbs2-0011" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Chinese Journal of Contemporary Pediatrics2012;14(7):502-5. [PMID: 22809601]">Lin 2012</a>); and one in the USA (<a href="./references#CD013278-bbs2-0012" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>). </p> </section> </section> <section id="CD013278-sec-0049"> <h4 class="title">Excluded studies</h4> <p>We excluded 30 studies for the following reasons:</p> <p> <ol id="CD013278-list-0010"> <li> <p>11 studies were excluded because the study population did not match our inclusion criteria, which stipulated that presence of an hs‐PDA must be confirmed based on the above mentioned clinical and/or echocardiographic criteria prior to inclusion in the study (<a href="./references#CD013278-bbs2-0019" title="CouserRJ , FerraraTB , WrightGB , CabalkaAK , SchillingCG , HoekstraRE , et al. Prophylactic indomethacin therapy in the first twenty-four hours of life for the prevention of patent ductus arteriosus in preterm infants treated prophylactically with surfactant in the delivery room. Journal of Pediatrics1996;128(5 Pt 1):631-7. [DOI: 10.1016/S0022-3476(96)80127-2] [PMID: 8627434]">Couser 1996</a>; <a href="./references#CD013278-bbs2-0021" title="JannatdoustA , SamadiM , YeganehdoustS , HeydarzadehM , AlikhahH , PiriR , et al. Effects of intravenous indomethacin on reduction of symptomatic patent ductus arteriosus cases and decreasing the need for prolonged mechanical ventilation. Journal of Cardiovascular and Thoracic Research2014;6(4):257-9. [DOI: 10.15171/jcvtr.2014.022] [PMID: 25610559]">Jannatdoust 2014</a>; <a href="./references#CD013278-bbs2-0024" title="MahonyL , CarneroV , BrettC , HeymannMA , ClymanRI . Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants. New England Journal of Medicine1982;306(9):506-10. [DOI: 10.1056/NEJM198203043060903] [PMID: 7035955]">Mahony 1982</a>; <a href="./references#CD013278-bbs2-0025" title="MahonyL , CaldwellRL , GirodDA , HurwitzRA , JanesenRD , LemondsJA , et al. Indomethacin therapy on the first day of life in infants with very low birth weight. Journal of Pediatrics1985;106(5):801-5. [DOI: 10.1016/S0022-3476(85)80361-9] [PMID: 3998921]">Mahony 1985</a>; <a href="./references#CD013278-bbs2-0026" title="MentLR , DuncanCC , EhrenkranzRA , KleinmanCS , PittBR , TaylorKJ , et al. Randomized indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight infants. Journal of Pediatrics1985;107(6):937-43. [DOI: 10.1016/S0022-3476(85)80197-9] [PMID: 3906073]">Ment 1985</a>; <a href="./references#CD013278-bbs2-0027" title="MentLR , DuncanCC , EhrenkranzRA , KleinmanCS , TaylorKJ , ScottDT , et al. Randomized low-dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates. Journal of Pediatrics1988;112(6):948-55. [DOI: 10.1016/S0022-3476(88)80225-7] [PMID: 3373405]">Ment 1988</a>; <a href="./references#CD013278-bbs2-0028" title="MentLR , OhW , EhrenkranzRA , PhillipAG , VohrB , AllanW , et al. Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial. Journal of Pediatrics1994;124(6):951-5. [DOI: 10.1016/S0022-3476(05)83191-9] [PMID: 8201485]">Ment 1994a</a>; <a href="./references#CD013278-bbs2-0029" title="MentLR , OhW , EhrenkranzRA , PhilipAG , VohrB , AllanW , et al. Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics1994;93(4):543-50. [PMID: 8134206]">Ment 1994b</a>; <a href="./references#CD013278-bbs2-0031" title="MullettMD , CroghanTW , MyerbergDZ , KrallJM , NealWA . Indomethacin for closure of patent ductus arteriosus in prematures. Clinical Pediatrics1982;21(4):217-20. [DOI: 10.1177/000992288202100404] [PMID: 7039927]">Mullett 1982</a>; <a href="./references#CD013278-bbs2-0036" title="RennieJM , DoyleJ , CookeRW . Early administration of indomethacin to preterm infants. Archives of Disease in Childhood1986;61(3):233-8. [DOI: 10.1136/adc.61.3.233] [PMID: 3516077]">Rennie 1986</a>; <a href="./references#CD013278-bbs2-0040" title="SangtawesinC , SangtawesinV , LertsutthiwongW , KanjanapattanakulW , KhoranaM , AyudhayaJK . Prophylaxis of symptomatic patent ductus arteriosus with oral ibuprofen in very low birth weight infants. Journal of the Medical Association of Thailand (Chotmaihet Thangphaet)2008;91 Suppl 3:S28-34. [PMID: 19255990]">Sangtawesin 2008</a>); </p> </li> <li> <p>Nine studies were excluded for starting pharmacotherapy for PDA later than the seven days which we used to define 'early management' (<a href="./references#CD013278-bbs2-0016" title="BabaeiH , NematiR , DaryoshiH . Closure of patent ductus arteriosus with oral acetaminophen in preterm neonates: a randomized trial. Biomedical Research and Therapy2018;5(2):2034-44. [DOI: 10.15419/bmrat.v5i02.418]">Babaei 2018</a>; <a href="./references#CD013278-bbs2-0018" title="ClymanRI , LiebowitzM , KaempfJ , ErdeveO , BulbulA , HÃƒÂ¥kanssonS , et al, PDA-TOLERATE (PDA: TO LEave it alone or Respond And Treat Early) Trial Investigators. PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age. Journal of Pediatrics2019;205:41-8.e6. [DOI: 10.1016/j.jpeds.2018.09.012] [PMID: 30340932]">Clyman 2019</a>; <a href="./references#CD013278-bbs2-0030" title="Monset-CouchardM , Dias-MancanoD , MuratI , RelierJP . Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants [Essai contrÃƒÂ´lÃƒÂ© de l'indomÃƒÂ©thacine lyophilisÃƒÂ©e intra-veineuse dans le traitement du canal artÃƒÂ©riel persistant du prÃƒÂ©maturÃƒÂ©]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset Couchard 1983</a>; <a href="./references#CD013278-bbs2-0032" title="NestrudRM , HillDE , ArringtonRW , BeardAG , DunganWT , LauPY , et al. Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Developmental Pharmacology and Therapeutics1980;1(2-3):125-36. [PMID: 6765467]">Nestrud 1980</a>; <a href="./references#CD013278-bbs2-0033" title="NeuJ , AriagnoRL , JohnsonJD , PitlickPT , CohenRS , BeetsCL , et al. A double blind study of the effects of oral indomethacin in preterm infants with patent ductus arteriosus who failed medical management. Pediatric Pharmacology1981;1(3):245-9. [PMID: 7346744]">Neu 1981</a>; <a href="./references#CD013278-bbs2-0037" title="RuddP , MontanezP , Hallidie SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a>; <a href="./references#CD013278-bbs2-0042" title="YanagiRM , WilsonA , NewfeldEA , AzizKU , HuntCE . Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics1981;67(5):647-52. [PMID: 7019841]">Yanagi 1981</a>; <a href="./references#CD013278-bbs2-0043" title="YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus - a double-blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/S0022-3476(81)80560-4] [PMID: 7005415]">Yeh 1981</a>; <a href="./references#CD013278-bbs2-0044" title="YehTF , GoldbargHR , HenekT , ThalijiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one-year follow-up. American Journal of Diseases of Children1982;136(9):803-7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]">Yeh 1982</a>) </p> </li> <li> <p>Three studies duplicated results from previous publications (<a href="./references#CD013278-bbs2-0017" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]">Betkerur 1981</a> (renal outcomes, providing no information about PDA closure); <a href="./references#CD013278-bbs2-0022" title="JuujÃƒÂ¤rviS , KallankariH , PÃƒÂ¤tsiP , LeskinenM , SaarelaT , HallmanM , et al. Follow-up study of the early, randomised paracetamol trial to preterm infants, found no adverse reactions at the two-years corrected age. Acta Paediatrica, International Journal of Paediatrics2019;108(3):452-8. [DOI: 10.1111/apa.14614] [PMID: 30325529]">Juujrvi 2019</a> ‐ results of <a href="./references#CD013278-bbs2-0020" title="HÃƒÂ¤rkinP , HÃƒÂ¤rmÃƒÂ¤A , AikioO , ValkamaM , LeskinenM , SaarelaT , et al. Paracetamol accelerates closure of the ductus arteriosus after prematureÃ‚Â birth: a randomized trial. Journal of Pediatrics2016;177:72-7.e2. [DOI: 10.1016/j.jpeds.2016.04.066] [PMID: 27215779]">Harkin 2016</a>, which was excluded as below; <a href="./references#CD013278-bbs2-0023" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. Journal of Paediatrics and Child Health2012;48:43-4. [DOI: 10.1111/j.1440-1754.2012.02411.x]">Kluckow 2012</a> ‐ abstract of <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>); </p> </li> <li> <p>Three studies included infants treated for indications outside our criteria (<a href="./references#CD013278-bbs2-0015" title="ArandaJV , ClymanR , CoxB , Van OvermeireB , WozniakP , SosenkoI , et al. A randomized, double-blind, placebo- controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants. American Journal of Perinatology2009;26(3):235-46. [DOI: 10.1055/s-0028-1103515] [PMID: 19067286]">Aranda 2009</a>; <a href="./references#CD013278-bbs2-0039" title="SangtawesinV , SangtawesinC , RaksasinborisutC , SathirakulK , KanjanapattanakulW , KhoranaM , et al. Oral ibuprofen prophylaxis for symptomatic patent ductus arteriosus of prematurity. Journal of the Medical Association of Thailand2006;89(3):314-21. [PMID: 16696414]">Sangtawesin 2006</a>; <a href="./references#CD013278-bbs2-0041" title="WeesnerKM , DillardRG , BoyleRJ , BlockSM . Prophylactic treatment of asymptomatic patent ductus arteriosus in premature infants with respiratory distress syndrome. Southern Medical Journal1987;80(6):706-8. [DOI: 10.1097/00007611-198706000-00010] [PMID: 3296225]">Weesner 1987</a>); </p> </li> <li> <p>One study included a comparator group which was not expectant management (<a href="./references#CD013278-bbs2-0038" title="SalamaH , AlsisiA , Al-RifaiH , ShaddadA , SamawalL , HabboubL , et al. A randomized controlled trial on the use of oral ibuprofen to close patent ductus arteriosus in premature infants. Journal of Neonatal-Perinatal Medicine2008;1:153‐8. ">Salama 2008</a>); </p> </li> <li> <p>One study used prophylactic treatment rather than diagnosing PDA prior to study inclusion (<a href="./references#CD013278-bbs2-0020" title="HÃƒÂ¤rkinP , HÃƒÂ¤rmÃƒÂ¤A , AikioO , ValkamaM , LeskinenM , SaarelaT , et al. Paracetamol accelerates closure of the ductus arteriosus after prematureÃ‚Â birth: a randomized trial. Journal of Pediatrics2016;177:72-7.e2. [DOI: 10.1016/j.jpeds.2016.04.066] [PMID: 27215779]">Harkin 2016</a>); </p> </li> <li> <p>One study was a cross‐over RCT, therefore effect of interventions on clinical outcomes could not be determined (<a href="./references#CD013278-bbs2-0034" title="OsbornDA , EvansN , KluckowM . Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant. Archives of Disease in Childhood: Fetal and Neonatal Edition2003;88(6):F477-82. [DOI: 10.1136/fn.88.6.f477] [PMID: 14602694]">Osborn 2003</a>); </p> </li> <li> <p>One study included no data on early management of PDA (<a href="./references#CD013278-bbs2-0035" title="PeckhamGJ , MiettinenOS , EllisonRC , KraybillEN , GersonyWM , ZierlerS , et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. Journal of Pediatrics1984;105(2):285-91. [DOI: 10.1016/s0022-3476(84)80134-1] [PMID: 6379136]">Peckham 1984</a>). </p> </li> </ol> </p> <p>For further details see <a href="./references#CD013278-sec-0177" title="">Characteristics of excluded studies</a> </p> </section> </section> <section id="CD013278-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>For the summary of the authors' judgements on the risk of bias in individual studies, please see <a href="#CD013278-fig-0002">Figure 2</a> and <a href="#CD013278-fig-0003">Figure 3</a>. One study was only available as a conference abstract with limited details and the corresponding author could not be contacted for further information (<a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a>). Thus, we were unable to make a judgement on the risk of bias in this study due to limited information. </p> <div class="figure" id="CD013278-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013278-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD013278-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013278-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD013278-sec-0051"> <h4 class="title">Allocation</h4> <p>The overall risk of selection bias was low. Randomization and allocation procedures were clearly described in nine studies (<a href="./references#CD013278-bbs2-0002" title="CTRI/2009/091/000041. RCT comparing indomethacin vs. no treatment for PDA on the basis of size in the first 24 hrs of life in preterm neonates between 28 to 32 weeks gestation requiring assisted ventilation. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=318&amp;EncHid=&amp;modid=&amp;compid=%27,%27318det%272010. ">CTRI/2009/091/000041</a>; <a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>; <a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a>; <a href="./references#CD013278-bbs2-0005" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]">Gersony 1983</a>; <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>; <a href="./references#CD013278-bbs2-0010" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78-81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013278-bbs2-0011" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Chinese Journal of Contemporary Pediatrics2012;14(7):502-5. [PMID: 22809601]">Lin 2012</a>; <a href="./references#CD013278-bbs2-0012" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>; <a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a>). There was insufficient information on randomization and allocation to allow us to make a judgement in four studies (<a href="./references#CD013278-bbs2-0001" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. Journal of Maternal-Fetal and Neonatal Medicine2013;26(4):423-9. [DOI: 10.3109/14767058.2012.733775] [PMID: 23057804]">Bagnoli 2013</a>; <a href="./references#CD013278-bbs2-0007" title="KaapaP , LanningP , KoivistoM . Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome. Acta Paediatrica Scandinavica1983;72(2):179-84. [DOI: 10.1111/j.1651-2227.1983.tb09693.x] [PMID: 6340412 ]">Kaapa 1983</a>; <a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a>; <a href="./references#CD013278-bbs2-0014" title="Van OvermeireB , Van De BroekH , Van LaerP , WeylerJ , VanhaesebrouckP . Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. Journal of Pediatrics2001;138(2):205-11. [DOI: 10.1067/mpd.2001.110528] [PMID: 11174617]">Van Overmeire 2001</a>). <a href="./references#CD013278-bbs2-0006" title="GhanemS , MostafaM , ShafeeM . Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. Journal of the Saudi Heart Association2010;22(1):7-12. [DOI: 10.1016/j.jsha.2010.01.002] [PMID: 23960586]">Ghanem 2010</a> included no details of the randomization process and appeared to randomize infants who had not yet been diagnosed with PDA, although they were only given treatment or placebo when a diagnosis of PDA was established. </p> </section> <section id="CD013278-sec-0052"> <h4 class="title">Blinding</h4> <p>Blinding processes were clearly described in five studies (<a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>; <a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a>; <a href="./references#CD013278-bbs2-0005" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]">Gersony 1983</a>; <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>; <a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a>). There was insufficient information in four studies (<a href="./references#CD013278-bbs2-0001" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. Journal of Maternal-Fetal and Neonatal Medicine2013;26(4):423-9. [DOI: 10.3109/14767058.2012.733775] [PMID: 23057804]">Bagnoli 2013</a>; <a href="./references#CD013278-bbs2-0006" title="GhanemS , MostafaM , ShafeeM . Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. Journal of the Saudi Heart Association2010;22(1):7-12. [DOI: 10.1016/j.jsha.2010.01.002] [PMID: 23960586]">Ghanem 2010</a>; <a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a>; <a href="./references#CD013278-bbs2-0011" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Chinese Journal of Contemporary Pediatrics2012;14(7):502-5. [PMID: 22809601]">Lin 2012</a>). Five studies provided either no information about blinding, or the staff giving treatments or assessing outcomes were not blinded (<a href="./references#CD013278-bbs2-0002" title="CTRI/2009/091/000041. RCT comparing indomethacin vs. no treatment for PDA on the basis of size in the first 24 hrs of life in preterm neonates between 28 to 32 weeks gestation requiring assisted ventilation. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=318&amp;EncHid=&amp;modid=&amp;compid=%27,%27318det%272010. ">CTRI/2009/091/000041</a>; <a href="./references#CD013278-bbs2-0007" title="KaapaP , LanningP , KoivistoM . Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome. Acta Paediatrica Scandinavica1983;72(2):179-84. [DOI: 10.1111/j.1651-2227.1983.tb09693.x] [PMID: 6340412 ]">Kaapa 1983</a>; <a href="./references#CD013278-bbs2-0010" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78-81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013278-bbs2-0012" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>; <a href="./references#CD013278-bbs2-0014" title="Van OvermeireB , Van De BroekH , Van LaerP , WeylerJ , VanhaesebrouckP . Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. Journal of Pediatrics2001;138(2):205-11. [DOI: 10.1067/mpd.2001.110528] [PMID: 11174617]">Van Overmeire 2001</a>). </p> </section> <section id="CD013278-sec-0053"> <h4 class="title">Incomplete outcome data</h4> <p>We judged 10 studies to be at low risk of attrition bias (<a href="./references#CD013278-bbs2-0001" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. Journal of Maternal-Fetal and Neonatal Medicine2013;26(4):423-9. [DOI: 10.3109/14767058.2012.733775] [PMID: 23057804]">Bagnoli 2013</a>; <a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>; <a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a>; <a href="./references#CD013278-bbs2-0005" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]">Gersony 1983</a>; <a href="./references#CD013278-bbs2-0006" title="GhanemS , MostafaM , ShafeeM . Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. Journal of the Saudi Heart Association2010;22(1):7-12. [DOI: 10.1016/j.jsha.2010.01.002] [PMID: 23960586]">Ghanem 2010</a>; <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>; <a href="./references#CD013278-bbs2-0010" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78-81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013278-bbs2-0011" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Chinese Journal of Contemporary Pediatrics2012;14(7):502-5. [PMID: 22809601]">Lin 2012</a>; <a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a>; <a href="./references#CD013278-bbs2-0014" title="Van OvermeireB , Van De BroekH , Van LaerP , WeylerJ , VanhaesebrouckP . Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. Journal of Pediatrics2001;138(2):205-11. [DOI: 10.1067/mpd.2001.110528] [PMID: 11174617]">Van Overmeire 2001</a>). Information was insufficient in three studies (<a href="./references#CD013278-bbs2-0002" title="CTRI/2009/091/000041. RCT comparing indomethacin vs. no treatment for PDA on the basis of size in the first 24 hrs of life in preterm neonates between 28 to 32 weeks gestation requiring assisted ventilation. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=318&amp;EncHid=&amp;modid=&amp;compid=%27,%27318det%272010. ">CTRI/2009/091/000041</a>; <a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a>; <a href="./references#CD013278-bbs2-0012" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>). We judged <a href="./references#CD013278-bbs2-0007" title="KaapaP , LanningP , KoivistoM . Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome. Acta Paediatrica Scandinavica1983;72(2):179-84. [DOI: 10.1111/j.1651-2227.1983.tb09693.x] [PMID: 6340412 ]">Kaapa 1983</a> to be at high risk of attrition bias, and the study reported incomplete outcomes. </p> </section> <section id="CD013278-sec-0054"> <h4 class="title">Selective reporting</h4> <p>We judged four studies to be at low risk of reporting bias (<a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>; <a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a>; <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>; <a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a>). The other studies provided incomplete information to allow us to make a judgement to be made on the risk of reporting bias. </p> </section> <section id="CD013278-sec-0055"> <h4 class="title">Other potential sources of bias</h4> <p>We judged that <a href="./references#CD013278-bbs2-0012" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a> had a significant risk of bias from other sources as the exclusion criteria were separately applied to the treatment group, making the treatment group and control group systematically different. </p> </section> </section> <section id="CD013278-sec-0056"> <h3 class="title" id="CD013278-sec-0056">Effects of interventions</h3> <p>See: <a href="./full#CD013278-tbl-0001"><b>Summary of findings 1</b> Early treatment compared to expectant management for preterm infants</a>; <a href="./full#CD013278-tbl-0002"><b>Summary of findings 2</b> Very early treatment compared to expectant management for preterm infants</a> </p> <section id="CD013278-sec-0057"> <h4 class="title">Comparison 1. Early treatment versus expectant management</h4> <p>See Summary of findings table 1.</p> <section id="CD013278-sec-0058"> <h5 class="title">Primary outcome</h5> <section id="CD013278-sec-0059"> <h6 class="title">All‐cause mortality during hospital stay</h6> <p>(<a href="./references#CD013278-fig-0007" title="">Analysis 1.1</a>) </p> <p>Six studies (n = 600) reported on this outcome. There were no statistically significant differences between the early treatment and expectant management groups in all‐cause mortality (typical RR 0.80, 95% CI 0.46 to 1.39; typical RD ‐0.02; 95% CI ‐0.07 to 0.03; I<sup>2</sup> = 0% for RR and for RD) (<a href="#CD013278-fig-0004">Figure 4</a>). We rated the certainty of evidence as moderate. </p> <div class="figure" id="CD013278-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Early treatment vs expectant management, outcome: 1.1 All‐cause mortality during hospital stay." data-id="CD013278-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Early treatment vs expectant management, outcome: 1.1 All‐cause mortality during hospital stay. </p> </div> </div> </div> <section id="CD013278-sec-0060"> <p><b>Subgroup analyses</b></p> <p>Three out of the six studies used IV indomethacin, two studies used IV ibuprofen and one study used oral ibuprofen. No statistically significant differences in all‐cause mortality were noted in either the indomethacin (typical RR 0.95, 95% CI 0.45 to 1.99; typical RD ‐0.01; 95% CI ‐0.09 to 0.08; I<sup>2</sup> = 0% for RR and for RD), or the ibuprofen subgroups (typical RR 0.65, 95% CI 0.28, to 1.50; typical RD ‐0.03; 95% CI ‐0.08 to 0.03; I<sup>2</sup> = 0% for RR and for RD). </p> </section> </section> </section> <section id="CD013278-sec-0061"> <h5 class="title">Secondary outcomes</h5> <section id="CD013278-sec-0062"> <h6 class="title">Proportion of infants requiring surgical PDA ligation or transcatheter occlusion</h6> <p>(<a href="./references#CD013278-fig-0008" title="">Analysis 1.2</a>) </p> <p>Four studies (n = 432) reported on this outcome. There were no statistically significant differences between the early treatment and expectant management groups in surgical PDA ligation (typical RR 1.08, 95% CI 0.65 to 1.80; typical RD ‐0.03; 95% CI ‐0.09 to 0.03; I<sup>2</sup> = 59% for RR and 76% for RD, respectively). We rated the certainty of evidence as very low. </p> <section id="CD013278-sec-0063"> <p><b>Subgroup analyses</b></p> <p>One out of the four studies used IV indomethacin, two studies used IV ibuprofen and one study used oral ibuprofen. No statistically significant differences in surgical PDA ligation were noted in either the indomethacin (typical RR 0.74, 95% CI 0.17 to 3.17; typical RD ‐0.02; 95% CI ‐0.10 to 0.06; test for heterogeneity not applicable), or the ibuprofen subgroups (typical RR 1.14, 95% CI 0.66, to 1.96; typical RD ‐0.04; 95% CI ‐0.12 to 0.04; I<sup>2</sup> = 71% for RR and 84% for RD, respectively) </p> </section> </section> <section id="CD013278-sec-0064"> <h6 class="title">Proportion of infants receiving any pharmacotherapy for a hemodynamically significant PDA (defined as any receipt of pharmacotherapy for a hemodynamically significant PDA any time during hospital stay) </h6> <p>(<a href="./references#CD013278-fig-0009" title="">Analysis 1.3</a>) </p> <p>Two studies (n = 232) reported on this outcome. There was a statistically significant difference between the early treatment and expectant management groups with regards to receipt of any pharmacotherapy for hs‐PDA favoring expectant management (typical RR 2.30, 95% CI 1.86 to 2.83; typical RD 0.57; 95% CI 0.48 to 0.66; I<sup>2</sup> = 0% for RR and for RD) (<a href="#CD013278-fig-0005">Figure 5</a>). We rated the certainty of evidence as low. </p> <div class="figure" id="CD013278-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Early treatment vs expectant management, outcome: 1.3 Receipt of any pharmacotherapy for a hemodynamically significant PDA." data-id="CD013278-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Early treatment vs expectant management, outcome: 1.3 Receipt of any pharmacotherapy for a hemodynamically significant PDA. </p> </div> </div> </div> <section id="CD013278-sec-0065"> <p><b>Subgroup analyses</b></p> <p>One study used IV indomethacin, and the other IV ibuprofen. Both studies demonstrated statistically significant differences in receipt of any pharmacotherapy for hs‐PDA favoring the expectant management group. </p> </section> </section> <section id="CD013278-sec-0066"> <h6 class="title">Proportion of infants receiving rescue medical treatment (COX inhibitor or acetaminophen dosing, or both) for a hemodynamically significant PDA </h6> <p>(<a href="./references#CD013278-fig-0010" title="">Analysis 1.4</a>) </p> <p>Two studies (n = 232) reported on this outcome. There were no statistically significant differences between the early treatment and expectant management groups (typical RR 0.63, 95% CI 0.27 to 1.48; typical RD ‐0.02; 95% CI ‐0.06 to 0.02; I<sup>2</sup> = 0% for RR and for RD). </p> <section id="CD013278-sec-0067"> <p><b>Subgroup analyses</b></p> <p>One study used IV indomethacin, and the other IV ibuprofen. None of the studies demonstrated statistically significant differences in receipt of rescue medical treatment for a hemodynamically significant PDA. </p> </section> </section> <section id="CD013278-sec-0068"> <h6 class="title">Chronic lung disease (CLD; defined as oxygen requirement at 36 weeks' postmenstrual age). </h6> <p>(<a href="./references#CD013278-fig-0011" title="">Analysis 1.5</a>) </p> <p>Four studies (n = 339) reported on this outcome. There were no statistically significant differences between the early treatment and expectant management groups in CLD (typical RR 0.90, 95% CI 0.62 to 1.29; typical RD ‐0.03; 95% CI ‐0.10 to 0.03; I<sup>2</sup> = 0% for RR and for RD). We rated the certainty of evidence as moderate. </p> <section id="CD013278-sec-0069"> <p><b>Subgroup analyses</b></p> <p>Two out of the four studies used IV indomethacin, one used IV ibuprofen, and one study used oral ibuprofen. No statistically significant differences in CLD were noted in either the indomethacin (typical RR 0.84, 95% CI 0.52 to 1.37; typical RD ‐0.06; 95% CI ‐0.20 to 0.07; I<sup>2</sup> = 0% for RR and for RD), or the ibuprofen subgroups (typical RR 0.97, 95% CI 0.56 to 1.69; typical RD ‐0.03; 95% CI ‐0.10 to 0.05; I<sup>2</sup> = 0% for RR and for RD). </p> </section> </section> <section id="CD013278-sec-0070"> <h6 class="title">Duration of ventilator support (days)</h6> <p>(<a href="./references#CD013278-fig-0012" title="">Analysis 1.6</a>) </p> <p>One study (n = 127) that used IV indomethacin reported on this outcome. There was no statistically significant difference between the early treatment and expectant management groups with respect to days on ventilator support (MD ‐13.40 days; 95% CI ‐30.15 to 3.35). The test for heterogeneity was not applicable. </p> </section> <section id="CD013278-sec-0071"> <h6 class="title">Duration of need for supplementary oxygen (days)</h6> <p>(<a href="./references#CD013278-fig-0013" title="">Analysis 1.7</a>) </p> <p>One study (n = 127) that used IV indomethacin reported on this outcome. There was no statistically significant difference between the early treatment and expectant management groups with respect to days on supplementary oxygen (MD ‐8.3 days; 95% CI ‐43.27 to 26.67). The test for heterogeneity was not applicable. </p> </section> <section id="CD013278-sec-0072"> <h6 class="title">Postnatal corticosteroid use for CLD any time during hospital stay</h6> <p>(<a href="./references#CD013278-fig-0014" title="">Analysis 1.8</a>) </p> <p>One study (n = 105) that used IV ibuprofen reported on this outcome. There was no statistically significant difference between the early treatment and expectant management groups with respect to postnatal corticosteroid use for CLD (typical RR 1.13, 95% CI 0.37 to 3.49; typical RD 0.01; 95% CI ‐0.10 to 0.13). The test for heterogeneity was not applicable. </p> </section> <section id="CD013278-sec-0073"> <h6 class="title">Pneumothorax</h6> <p>(<a href="./references#CD013278-fig-0015" title="">Analysis 1.9</a>) </p> <p>Two studies (n = 146) reported on this outcome. There was no statistically significant difference between the early treatment and expectant management groups in pneumothorax (typical RR 0.88, 95% CI 0.32 to 2.42; typical RD 0.00; 95% CI ‐0.09 to 0.09; I<sup>2</sup> = 0% for RR and for RD). </p> <section id="CD013278-sec-0074"> <p><b>Subgroup analyses</b></p> <p>One study used IV indomethacin, and the other IV ibuprofen. None of the studies showed any significant differences in pneumothorax between the two groups. </p> </section> </section> <section id="CD013278-sec-0075"> <h6 class="title">Intraventricular hemorrhage (IVH) (grades I to IV)</h6> <p>(<a href="./references#CD013278-fig-0016" title="">Analysis 1.10</a>) </p> <p>Three studies (n = 234) reported on this outcome. There were no statistically significant differences between the early treatment and expectant management groups in IVH (typical RR 0.91, 95% CI 0.34 to 2.48; typical RD 0.01; 95% CI ‐0.20 to 0.14; I<sup>2</sup> = 39% for RR and 73% for RD, respectively). </p> <section id="CD013278-sec-0076"> <p><b>Subgroup analyses</b></p> <p>Two out of the three studies used IV indomethacin and one used oral. No statistically significant differences in IVH were noted in either the indomethacin (typical RR 1.19, 95% CI 0.21 to 6.60; typical RD 0.02; 95% CI ‐0.05 to 0.08; I<sup>2</sup> = 68% for RR and 86% for RD, respectively) or the ibuprofen subgroups (typical RR 0.80, 95% CI 0.24 to 2.72; typical RD ‐0.03; 95% CI ‐0.20 to 0.14; test for heterogeneity not applicable). </p> </section> </section> <section id="CD013278-sec-0077"> <h6 class="title">Severe IVH (grades III and IV)</h6> <p>(<a href="./references#CD013278-fig-0017" title="">Analysis 1.11</a>) </p> <p>Two studies (n = 171) reported on this outcome. One study used oral ibuprofen, and the other IV ibuprofen. There were no statistically significant differences between the early treatment and expectant management groups in severe IVH (typical RR 0.83, 95% CI 0.32 to 2.16; typical RD ‐0.01; 95% CI ‐0.08 to 0.06; I<sup>2</sup> = 0% for both RR and RD). We rated the certainty of evidence as low. </p> </section> <section id="CD013278-sec-0078"> <h6 class="title">Periventricular leukomalacia (PVL; any grade)</h6> <p>(<a href="./references#CD013278-fig-0018" title="">Analysis 1.12</a>) </p> <p>Three studies (n = 298) reported on this outcome. There were no statistically significant differences between the early treatment and expectant management groups in PVL (typical RR 1.22, 95% CI 0.55 to 2.75; typical RD 0.03; 95% CI ‐0.03 to 0.08; I<sup>2</sup> = 0% for both RR and RD). </p> <section id="CD013278-sec-0079"> <p><b>Subgroup analyses</b></p> <p>One out of the three studies used IV indomethacin, one used oral ibuprofen, and one study used IV ibuprofen. No statistically significant differences in PVL were noted in either the indomethacin (typical RR 2.46, 95% CI 0.50 to 12.22; typical RD 0.05; 95% CI ‐0.03 to 0.13; test for heterogeneity not applicable) or the ibuprofen subgroups (typical RR 0.97, 95% CI 0.38 to 2.46; typical RD 0.00; 95% CI ‐0.08 to 0.09; I<sup>2</sup> = 0% for both RR and RD). </p> </section> </section> <section id="CD013278-sec-0080"> <h6 class="title">Necrotizing enterocolitis (NEC; stage 2 or greater)</h6> <p>(<a href="./references#CD013278-fig-0019" title="">Analysis 1.13</a>) </p> <p>Five studies (n = 473) reported on this outcome. There were no statistically significant differences between the early treatment and expectant management groups in NEC (typical RR 2.34, 95% CI 0.86 to 6.41; typical RD 0.04; 95% CI 0.01 to 0.08; I<sup>2</sup> = 10% for RR and 51% for RD, respectively). We rated the certainty of evidence as low. </p> <section id="CD013278-sec-0081"> <p><b>Subgroup analyses</b></p> <p>Two out of the five studies used IV indomethacin, two used IV ibuprofen, and one study used oral ibuprofen. No statistically significant differences in NEC were noted in either the indomethacin (typical RR 1.56, 95% CI 0.28 to 8.80; typical RD 0.02; 95% CI ‐0.04 to 0.08; I<sup>2</sup> = 49% for RR and 69% for RD, respectively) or the ibuprofen subgroups (typical RR 2.89, 95% CI 0.84 to 9.95; typical RD 0.06; 95% CI 0.01 to 0.11; I<sup>2</sup> = 7% for RR and 51% for RD, respectively). </p> </section> </section> <section id="CD013278-sec-0082"> <h6 class="title">Spontaneous intestinal perforation</h6> <p>(<a href="./references#CD013278-fig-0020" title="">Analysis 1.14</a>) </p> <p>Three studies (n = 298) reported on this outcome. There were no statistically significant differences between the early treatment and expectant management groups in spontaneous intestinal perforation (typical RR 0.57, 95% CI 0.14 to 2.37; typical RD ‐0.01; 95% CI ‐0.04 to 0.03; I<sup>2</sup> = 0% for both RR and RD). </p> <section id="CD013278-sec-0083"> <p><b>Subgroup analyses</b></p> <p>One out of the three studies used IV indomethacin, one used oral ibuprofen, and one study used IV ibuprofen. No statistically significant differences in spontaneous intestinal perforation were noted in either the indomethacin (typical RR 0.98, 95% CI 0.06 to 15.40; typical RD ‐0.00; 95% CI ‐0.04 to 0.04; test for heterogeneity not applicable), or the ibuprofen subgroups (typical RR 0.47, 95% CI 0.09 to 2.47; typical RD ‐0.01; 95% CI ‐0.06 to 0.04; I<sup>2</sup> = 0% for both RR and RD). </p> </section> </section> <section id="CD013278-sec-0084"> <h6 class="title">Time to full enteral feeds (postnatal age at time of achieving full enteral feeds)</h6> <p>(<a href="./references#CD013278-fig-0021" title="">Analysis 1.15</a>) </p> <p>One study (n = 66) that used oral ibuprofen reported on this outcome. There was a statistically significant difference between the early treatment and expectant management groups with regards to time to full enteral feeds favoring early treatment (MD ‐4.8 days; 95% CI ‐8.55 to ‐1.05). The test for heterogeneity was not applicable. </p> </section> <section id="CD013278-sec-0085"> <h6 class="title">Time to regain birth weight (days)</h6> <p>(<a href="./references#CD013278-fig-0022" title="">Analysis 1.16</a>) </p> <p>One study (n = 66) that used oral ibuprofen reported on this outcome. There was a statistically significant difference between the early treatment and expectant management groups with regards to time to regain birth weight favoring early treatment (MD ‐3.4 days; 95% CI ‐6.13 to ‐0.67). The test for heterogeneity was not applicable. </p> </section> <section id="CD013278-sec-0086"> <h6 class="title">Severe retinopathy of prematurity (ROP) (stage 3 or greater) (according to the international classification of ROP) </h6> <p>(<a href="./references#CD013278-fig-0023" title="">Analysis 1.17</a>) </p> <p>Two studies (n = 146) reported on this outcome. There was no statistically significant difference between the early treatment and expectant management groups in severe ROP (typical RR 1.30, 95% CI 0.44 to 3.84; typical RD ‐0.01; 95% CI ‐0.10 to 0.09; I<sup>2</sup> = 14% for RR and 62% for RD, respectively). </p> <section id="CD013278-sec-0087"> <p><b>Subgroup analyses</b></p> <p>One study used IV indomethacin, and the other IV ibuprofen. None of the studies showed any statistically significant differences in severe ROP between the two groups. </p> </section> </section> <section id="CD013278-sec-0088"> <h6 class="title">Definite sepsis (clinical symptoms and signs of sepsis and a positive bacterial culture in a specimen obtained from normally sterile fluids or tissue obtained at postmortem) </h6> <p>(<a href="./references#CD013278-fig-0024" title="">Analysis 1.18</a>) </p> <p>Four studies (n = 339) reported on this outcome. There were no statistically significant differences between the early treatment and expectant management groups in definite sepsis (typical RR 0.97, 95% CI 0.68 to 1.38; typical RD 0.00; 95% CI ‐0.08 to 0.09; I<sup>2</sup> = 0% for both RR and RD). </p> <section id="CD013278-sec-0089"> <p><b>Subgroup analyses</b></p> <p>Two of the four studies used IV indomethacin, one used oral ibuprofen, and one study used IV ibuprofen. No statistically significant differences in definite sepsis were noted in either the indomethacin (typical RR 1.16, 95% CI 0.56 to 2.41; typical RD 0.02; 95% CI ‐0.09 to 0.13; I<sup>2</sup> = 0% for both RR and RD) or the ibuprofen subgroups (typical RR 0.92, 95% CI 0.61 to 1.38; typical RD ‐0.02; 95% CI ‐0.15 to 0.11; I<sup>2</sup> = 0% for both RR and RD). </p> </section> </section> <section id="CD013278-sec-0090"> <h6 class="title">Oliguria (defined as less than 1 mL/kg/hour)</h6> <p>(<a href="./references#CD013278-fig-0025" title="">Analysis 1.19</a>) </p> <p>Two studies (n = 261) reported on this outcome. There was a statistically significant difference between the early treatment and expectant management groups in oliguria favoring the expectant management group (typical RR 6.41, 95% CI 2.13 to 19.26; typical RD 0.23; 95% CI 0.15 to 0.31; I<sup>2</sup> = 48% for RR and 49% for RD, respectively). </p> <section id="CD013278-sec-0091"> <p><b>Subgroup analyses</b></p> <p>One study used IV indomethacin, and the other IV ibuprofen. Both studies demonstrated a statistically significant difference between the early treatment and expectant management groups in oliguria favoring the expectant management group (IV indomethacin: typical RR 4.59, 95% CI 1.39 to 15.21; typical RD 0.17; 95% CI 0.06 to 0.29; test for heterogeneity not applicable; IV ibuprofen: typical RR 39.00, 95% CI 2.40 to 633.01; typical RD 0.28; 95% CI 0.17 to 0.39; test for heterogeneity not applicable). </p> <p>None of the studies included in this comparison reported on the proportion of infants receiving repeat courses of pharmacotherapy for a persistent hs‐PDA, pulmonary hemorrhage, pulmonary hypertension, gastrointestinal bleeding, duration of hospitalization or any neurodevelopmental outcomes. </p> </section> </section> </section> </section> <section id="CD013278-sec-0092"> <h4 class="title">Comparison 2. Very early treatment versus expectant management</h4> <p>See Summary of findings table 2.</p> <section id="CD013278-sec-0093"> <h5 class="title">Primary outcome</h5> <section id="CD013278-sec-0094"> <h6 class="title">All‐cause mortality during hospital stay</h6> <p>(<a href="./references#CD013278-fig-0026" title="">Analysis 2.1</a>) </p> <p>Seven studies (n = 384) reported on this outcome. There were no statistically significant differences between the very early treatment and expectant management groups in all‐cause mortality (typical RR 0.94, 95% CI 0.58 to 1.53; typical RD ‐0.03; 95% CI ‐0.09 to 0.04; I<sup>2</sup> = 16% for RR and 26% for RD, respectively) (<a href="#CD013278-fig-0006">Figure 6</a>). We rated the certainty of evidence as moderate. </p> <div class="figure" id="CD013278-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Very early treatment vs expectant management, outcome: 2.1 All‐cause mortality during hospital stay." data-id="CD013278-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Very early treatment vs expectant management, outcome: 2.1 All‐cause mortality during hospital stay. </p> </div> </div> </div> <section id="CD013278-sec-0095"> <p><b>Subgroup analyses</b></p> <p>Four out of the seven studies used indomethacin, two studies used ibuprofen and one study was a two‐center study that used indomethacin in one center and ibuprofen in the other. No significant differences in all‐cause mortality were noted in the indomethacin only subgroup (typical RR 0.92, 95% CI 0.47 to 1.80; typical RD ‐0.04; 95% CI ‐0.14 to 0.06; I<sup>2</sup> = 26% for RR and 37% for RD, respectively), the ibuprofen only subgroup (typical RR 1.46, 95% CI 0.58, to 3.67; typical RD 0.02; 95% CI ‐0.09 to 0.13; I<sup>2</sup> = 11% for RR and 45% for RD, respectively), or the subgroup with use of either indomethacin or ibuprofen (typical RR 0.53, 95% CI 0.17, to 1.60; typical RD ‐0.10; 95% CI ‐0.27 to 0.07; test for heterogeneity not applicable). </p> </section> </section> </section> <section id="CD013278-sec-0096"> <h5 class="title">Secondary outcomes</h5> <section id="CD013278-sec-0097"> <h6 class="title">Proportion of infants requiring surgical PDA ligation or transcatheter occlusion</h6> <p>(<a href="./references#CD013278-fig-0027" title="">Analysis 2.2</a>) </p> <p>Five studies (n = 293) reported on this outcome. There were no statistically significant differences between the very early treatment and expectant management groups in surgical PDA ligation or transcatheter occlusion (typical RR 0.88, 95% CI 0.36 to 2.17; typical RD ‐0.01; 95% CI ‐0.05 to 0.02; I<sup>2</sup> = 0% for both RR and RD). We rated the certainty of evidence as moderate. </p> <p>Three out of the five studies used indomethacin, one study used intravenous ibuprofen and one was a two‐center study that used indomethacin in one center and ibuprofen in the other. No significant differences in surgical PDA ligation or transcatheter occlusion were noted in the indomethacin only subgroup (typical RR 0.54, 95% CI 0.07 to 3.93; typical RD ‐0.02; 95% CI ‐0.07 to 0.03; I<sup>2</sup> = 0% for RR and for RD), the ibuprofen only subgroup (typical RR 1.00, 95% CI 0.36, to 2.75; typical RD 0.00; 95% CI ‐0.20 to 0.20; test for heterogeneity not applicable), or the subgroup with use of either indomethacin or ibuprofen (typical RR not estimable; typical RD 0.00; 95% CI ‐0.05 to 0.05; test for heterogeneity not applicable). </p> </section> <section id="CD013278-sec-0098"> <h6 class="title">Proportion of infants receiving any pharmacotherapy for a hemodynamically significant PDA (defined as any receipt of pharmacotherapy for a hemodynamically significant PDA any time during hospital stay) </h6> <p>(<a href="./references#CD013278-fig-0028" title="">Analysis 2.3</a>) </p> <p>Four studies (n = 156) reported on this outcome. There was a statistically significant difference between the very early treatment and expectant management groups with respect to receipt of any pharmacotherapy for a hemodynamically significant PDA favoring the expectant management group (typical RR 1.64, 95% CI 1.31 to 2.05; typical RD 0.69; 95% CI 0.60 to 0.79; I<sup>2</sup> = 87% for RR and 90% for RD, respectively). We rated the certainty of evidence as very low. </p> <section id="CD013278-sec-0099"> <p><b>Subgroup analyses</b></p> <p>Three out of the four studies used indomethacin, and one study used intravenous ibuprofen. Statistically significant differences in receipt of any pharmacotherapy for a hemodynamically significant PDA were noted for both the indomethacin subgroup (typical RR 1.42, 95% CI 1.10 to 1.82; typical RD 0.70; 95% CI 0.59 to 0.81; I<sup>2</sup> = 88% for RR and 93% for RD, respectively) as well as the ibuprofen group (typical RR 2.90, 95% CI 1.77 to 4.76; typical RD 0.67; 95% CI 0.49 to 0.84; test for heterogeneity not applicable). </p> </section> </section> <section id="CD013278-sec-0100"> <h6 class="title">Proportion of infants receiving repeat courses of pharmacotherapy (repeated COX inhibitor or acetaminophen dosing, or both) for a persistent hemodynamically significant PDA </h6> <p>(<a href="./references#CD013278-fig-0029" title="">Analysis 2.4</a>) </p> <p>Three studies (n = 133) reported on this outcome. There were no statistically significant differences between the very early treatment and expectant management groups with respect to receipt of repeat courses of pharmacotherapy for a persistent hemodynamically significant PDA (typical RR 1.99, 95% CI 0.50 to 7.94; typical RD 0.05; 95% CI ‐0.03 to 0.14; I<sup>2</sup> = 12% for RR and 30% for RD, respectively). </p> <section id="CD013278-sec-0101"> <p><b>Subgroup analyses</b></p> <p>Two out of the three studies used indomethacin, and one study used ibuprofen. No significant differences in receipt of repeat courses of pharmacotherapy were noted in the indomethacin only (typical RR 1.39, 95% CI 0.29 to 6.66; typical RD 0.00; 95% CI ‐0.13 to 0.13; I<sup>2</sup> = 26% for RR and 44% for RD, respectively) or the ibuprofen only subgroups (typical RR 7.00, 95% CI 0.38, to 130.26; typical RD ‐0.03; 95% CI ‐0.02 to 0.21; test for heterogeneity not applicable). </p> </section> </section> <section id="CD013278-sec-0102"> <h6 class="title">Proportion of infants receiving rescue medical treatment (COX inhibitor or acetaminophen dosing, or both) for a hemodynamically significant PDA </h6> <p>(<a href="./references#CD013278-fig-0030" title="">Analysis 2.5</a>) </p> <p>Two studies (n = 164) reported on this outcome. There were no statistically significant differences between the very early treatment and expectant management groups (typical RR 0.54, 95% CI 0.28 to 1.04; typical RD ‐0.03; 95% CI ‐0.10 to 0.04; I<sup>2</sup> = 0% for RR and 73% for RD, respectively). </p> <section id="CD013278-sec-0103"> <p><b>Subgroup analyses</b></p> <p>One study used IV indomethacin, and the other was a two‐center study that used indomethacin in one center and ibuprofen in the other. None of the studies demonstrated statistically significant differences in receipt of rescue medical treatment for a hemodynamically significant PDA. </p> </section> </section> <section id="CD013278-sec-0104"> <h6 class="title">Chronic lung disease (CLD; defined as oxygen requirement at 36 weeks' postmenstrual age) </h6> <p>(<a href="./references#CD013278-fig-0031" title="">Analysis 2.6</a>) </p> <p>Seven studies (n = 384) reported on this outcome. There were no statistically significant differences between the very early treatment and expectant management groups in CLD (typical RR 0.83, 95% CI 0.63 to 1.08; typical RD ‐0.05; 95% CI ‐0.13 to 0.04; I<sup>2</sup> = 48% for RR and 68% for RD, respectively). We rated the certainty of evidence as low. </p> <p>Four out of the seven studies used indomethacin, two studies used ibuprofen and one study was a two‐center study that used indomethacin in one center and ibuprofen in the other. There was a statistically significant difference between the very early treatment and expectant management groups in the ibuprofen only subgroup favoring very early treatment (typical RR 0.54, 95% CI 0.35, to 0.83; typical RD ‐0.26; 95% CI ‐0.42 to ‐0.09 I<sup>2</sup> = 0% for both RR and RD). No significant differences in CLD were noted in the indomethacin only subgroup (typical RR 1.06, 95% CI 0.61 to 1.83; typical RD 0.02; 95% CI ‐0.09 to 0.12; I<sup>2</sup> = 43% for RR and 70% for RD, respectively) or the subgroup with use of either indomethacin or ibuprofen (typical RR 1.12, 95% CI 0.71, to 1.75; typical RD 0.06; 95% CI ‐0.17 to 0.29; test for heterogeneity not applicable). </p> </section> <section id="CD013278-sec-0105"> <h6 class="title">Duration of ventilator support (days)</h6> <p>(<a href="./references#CD013278-fig-0032" title="">Analysis 2.7</a>) </p> <p>Six studies (n = 253) reported on this outcome. There was a statistically significant difference between the very early treatment and expectant management groups with respect to duration of ventilator support favoring very early treatment (MD ‐0.44 days; 95% CI ‐0.75 to ‐0.16; I<sup>2</sup> = 0%). </p> <section id="CD013278-sec-0106"> <p><b>Subgroup analyses</b></p> <p>Three out of the six studies used indomethacin, two studies used ibuprofen and one study was a two‐center study that used indomethacin in one center and ibuprofen in the other. Statistically significant differences in duration of ventilator support favoring very early treatment were noted in the indomethacin only subgroup (MD ‐1.37 days; 95% CI ‐2.70 to ‐0.04; I<sup>2</sup> = 0%), and the ibuprofen only subgroup (MD ‐0.41 days; 95% CI ‐0.71 to ‐0.11; I<sup>2</sup> = 0%) but not in the subgroup with use of either indomethacin or ibuprofen (MD 6.00 days; 95% CI ‐6.69 to 18.69; test for heterogeneity not applicable). </p> </section> </section> <section id="CD013278-sec-0107"> <h6 class="title">Duration of need for supplementary oxygen (days)</h6> <p>(<a href="./references#CD013278-fig-0033" title="">Analysis 2.8</a>) </p> <p>Three studies (n = 127) reported on this outcome. There were no statistically significant differences between the very early treatment and expectant management groups with respect to duration of need for supplementary oxygen (MD ‐1.73 days; 95% CI ‐3.99 to 0.53; I<sup>2</sup> = 0%). </p> <section id="CD013278-sec-0108"> <p><b>Subgroup analyses</b></p> <p>Two out of the three studies used indomethacin and one study used ibuprofen. There were no statistically significant differences between the very early treatment and expectant management groups with respect to duration of need for supplementary oxygen either in the indomethacin (MD ‐1.61 days; 95% CI ‐3.95 to 0.74; I<sup>2</sup> = 0%) or ibuprofen (MD ‐3.30 days; 95% CI ‐11.83 to 5.23; test for heterogeneity not applicable) subgroups. </p> </section> </section> <section id="CD013278-sec-0109"> <h6 class="title">Postnatal corticosteroid use for CLD any time during hospital stay</h6> <p>(<a href="./references#CD013278-fig-0034" title="">Analysis 2.9</a>) </p> <p>Three studies (n = 224) reported on this outcome. There was a statistically significant difference between the very early treatment and expectant management groups with respect to postnatal corticosteroid use for CLD favoring expectant management (typical RR 2.11, 95% CI 1.12 to 3.97; typical RD 0.11; 95% CI 0.01 to 0.20; I<sup>2</sup> = 0% for both RR and RD). </p> <section id="CD013278-sec-0110"> <p><b>Subgroup analyses</b></p> <p>One study used indomethacin, one study used ibuprofen and the other was a two‐center study that used indomethacin in one center and ibuprofen in the other. None of the studies individually demonstrated a statistically significant difference between the very early treatment and expectant management groups with respect to postnatal corticosteroid use for CLD (Indomethacin only subgroup: typical RR 1.91, 95% CI 0.60 to 6.08; typical RD 0.08; 95% CI ‐0.06 to 0.21; test for heterogeneity not applicable; Ibuprofen only subgroup: typical RR 2.50, 95% CI 0.53 to 11.89; typical RD 0.10; 95% CI ‐0.06 to 0.26; test for heterogeneity not applicable; Indomethacin or ibuprofen subgroup: typical RR 2.11, 95% CI 0.89 to 5.02; typical RD 0.18; 95% CI ‐0.02 to 0.38; test for heterogeneity not applicable). </p> </section> </section> <section id="CD013278-sec-0111"> <h6 class="title">Pulmonary hemorrhage</h6> <p>(<a href="./references#CD013278-fig-0035" title="">Analysis 2.10</a>) </p> <p>Five studies (n = 332) reported on this outcome. There were no statistically significant differences between the very early treatment and expectant management groups in pulmonary hemorrhage (typical RR 0.58, 95% CI 0.30 to 1.11; typical RD ‐0.03; 95% CI ‐0.08 to 0.02; I<sup>2</sup> = 0% for RR and 26% for RD, respectively). </p> <section id="CD013278-sec-0112"> <p><b>Subgroup analyses</b></p> <p>Two out of the five studies used indomethacin, two studies used ibuprofen and one study was a two‐center study that used indomethacin in one center and ibuprofen in the other. No significant differences in pulmonary hemorrhage were noted in the indomethacin only subgroup (typical RR 0.59, 95% CI 0.22 to 1.53; typical RD ‐0.04; 95% CI ‐0.15 to 0.07; I<sup>2</sup> = 62% for RR and 75% for RD, respectively), the ibuprofen only subgroup (typical RR 0.59, 95% CI 0.24, to 1.49; typical RD ‐0.02; 95% CI ‐0.10 to 0.06; I<sup>2</sup> = 0%), or the subgroup with use of either indomethacin or ibuprofen (typical RR 0.35, 95% CI 0.01, to 8.36; typical RD ‐0.03; 95% CI ‐0.10 to 0.05; test for heterogeneity not applicable). </p> </section> </section> <section id="CD013278-sec-0113"> <h6 class="title">Intraventricular hemorrhage (IVH) (grades I to IV)</h6> <p>(<a href="./references#CD013278-fig-0036" title="">Analysis 2.11</a>) </p> <p>Three studies (n = 200) reported on this outcome. There were no statistically significant differences between the very early treatment and expectant management groups in IVH (typical RR 0.70, 95% CI 0.44 to 1.10; typical RD ‐0.07; 95% CI ‐0.16 to 0.02; I<sup>2</sup> = 0% for RR and 2% for RD, respectively). </p> <section id="CD013278-sec-0114"> <p><b>Subgroup analyses</b></p> <p>Two out of the 3 studies used indomethacin and 1 study used ibuprofen. No significant differences in IVH were noted in the indomethacin only subgroup (typical RR 0.75, 95% CI 0.27 to 2.10; typical RD ‐0.05; 95% CI ‐0.15 to 0.05; I<sup>2</sup> = 34% for RR and 2% for RD, respectively) or the ibuprofen only subgroup (typical RR 0.68, 95% CI 0.41, to 1.14; typical RD ‐0.19; 95% CI ‐0.43 to 0.05; test for heterogeneity not applicable). </p> </section> </section> <section id="CD013278-sec-0115"> <h6 class="title">Severe IVH (grades III and IV)</h6> <p>(<a href="./references#CD013278-fig-0037" title="">Analysis 2.12</a>) </p> <p>Four studies (n = 240) reported on this outcome. There were no statistically significant differences between the very early treatment and expectant management groups in severe IVH (typical RR 0.64, 95% CI 0.21 to 1.93; typical RD ‐0.02; 95% CI ‐0.07 to 0.04; I<sup>2</sup> = 0% for both RR and RD). We rated the certainty of evidence as moderate. </p> <section id="CD013278-sec-0116"> <p><b>Subgroup analyses</b></p> <p>One out of the four studies used indomethacin, two studies used ibuprofen and one study was a two‐center study that used indomethacin in one center and ibuprofen in the other. No significant differences in severe intraventricular hemorrhage were noted in the indomethacin only subgroup (typical RR 1.00, 95% CI 0.07 to 15.00; typical RD 0.00; 95% CI ‐0.12 to 0.12; test for heterogeneity not applicable), the ibuprofen only subgroup (typical RR 0.67, 95% CI 0.11 to 3.98; typical RD ‐0.01; 95% CI ‐0.08 to 0.05; I<sup>2</sup> = 0%) or the subgroup with use of either indomethacin or ibuprofen (typical RR 0.53, 95% CI 0.10 to 2.71; typical RD ‐0.05; 95% CI ‐0.18 to 0.08; test for heterogeneity not applicable). </p> </section> </section> <section id="CD013278-sec-0117"> <h6 class="title">Periventricular leukomalacia (PVL; any grade)</h6> <p>(<a href="./references#CD013278-fig-0038" title="">Analysis 2.13</a>) </p> <p>Five studies (n = 332) reported on this outcome. There were no statistically significant differences between the very early treatment and expectant management groups in PVL (typical RR 0.61, 95% CI 0.31 to 1.20; typical RD 0.00; 95% CI ‐0.04 to 0.04; I<sup>2</sup> = 61% for both RR and RD, respectively). </p> <section id="CD013278-sec-0118"> <p><b>Subgroup analyses</b></p> <p>Two out of the five studies used indomethacin, two used ibuprofen and one study was a two‐center study that used indomethacin in one center and ibuprofen in the other. No significant differences in periventricular leukomalacia were noted in the indomethacin only subgroup (typical RR 1.09, 95% CI 0.29 to 4.10; typical RD 0.00; 95% CI ‐0.07 to 0.07; test for heterogeneity not applicable for RR; I<sup>2</sup> = 0% for RD) or the ibuprofen only subgroup (typical RR 0.50, 95% CI 0.23 to 1.10; typical RD 0.02; 95% CI ‐0.09 to 0.14; I<sup>2</sup> = 76% for RR and 90% for RD, respectively). The effect estimates for the subgroup with use of either indomethacin or ibuprofen could not be computed as there were no events in either arm in that subgroup. </p> </section> </section> <section id="CD013278-sec-0119"> <h6 class="title">Necrotizing enterocolitis (NEC; stage 2 or greater)</h6> <p>(<a href="./references#CD013278-fig-0039" title="">Analysis 2.14</a>) </p> <p>Five studies (n = 332) reported on this outcome. There were no statistically significant differences between the very early treatment and expectant management groups in NEC (typical RR 1.08, 95% CI 0.53 to 2.21; typical RD 0.01; 95% CI ‐0.04 to 0.06; I<sup>2</sup> = 0% for both RR and RD). We rated the certainty of evidence as moderate. </p> <section id="CD013278-sec-0120"> <p><b>Subgroup analyses</b></p> <p>Two out of the five studies used indomethacin, two used ibuprofen and one study was a two‐center study that used indomethacin in one center and ibuprofen in the other. No significant differences in NEC were noted in the indomethacin only subgroup (typical RR 0.80, 95% CI 0.18 to 3.49; typical RD ‐0.01; 95% CI ‐0.08 to 0.06; I<sup>2</sup> = 0% for both RR and RD), the ibuprofen only subgroup (typical RR 1.01, 95% CI 0.42, to 2.44; typical RD ‐0.01; 95% CI ‐0.13 to 0.11; I<sup>2</sup> = 2% for RR and 4% for RD, respectively) or the subgroup with use of either indomethacin or ibuprofen (typical RR 3.17, 95% CI 0.35, to 29.07; typical RD 0.06; 95% CI ‐0.05 to 0.17; test for heterogeneity not applicable). </p> </section> </section> <section id="CD013278-sec-0121"> <h6 class="title">Gastrointestinal bleeding within seven days of the first dose of pharmacotherapy</h6> <p>(<a href="./references#CD013278-fig-0040" title="">Analysis 2.15</a>) </p> <p>Two studies (n = 164) reported on this outcome. One study used indomethacin and the other study was a two‐center study that used indomethacin in one center and ibuprofen in the other. None of the studies reported any event of gastrointestinal bleeding. Therefore, the effect estimates could not be computed for this outcome. </p> <p><b>Spontaneous intestinal perforation</b> </p> <p>(<a href="./references#CD013278-fig-0041" title="">Analysis 2.16</a>) </p> <p>Four studies (n = 272) reported on this outcome. There were no statistically significant differences between the very early treatment and expectant management groups in spontaneous intestinal perforation (typical RR 0.96, 95% CI 0.15 to 6.36; typical RD 0.00; 95% CI ‐0.03 to 0.03; I<sup>2</sup> = 0% for both RR and RD). </p> <section id="CD013278-sec-0122"> <p><b>Subgroup analyses</b></p> <p>Two out of the four studies used indomethacin, one study used ibuprofen and one study was a two‐center study that used indomethacin in one center and ibuprofen in the other. No significant differences in spontaneous intestinal perforation were noted in the ibuprofen only subgroup (typical RR 0.50, 95% CI 0.05, to 5.24; typical RD ‐0.03; 95% CI ‐0.13 to 0.07; test for heterogeneity not applicable), or the subgroup with use of either indomethacin or ibuprofen (typical RR 3.17, 95% CI 0.13, to 75.24; typical RD 0.03; 95% CI ‐0.05 to 0.10; test for heterogeneity not applicable). The study using indomethacin did not report any event of spontaneous intestinal perforation. Therefore, the effect estimates could not be computed for this comparison. </p> </section> </section> <section id="CD013278-sec-0123"> <h6 class="title">Time to full enteral feeds (postnatal age at time of achieving full enteral feeds)</h6> <p>(<a href="./references#CD013278-fig-0042" title="">Analysis 2.17</a>) </p> <p>Two studies (n = 136) reported on this outcome. Both studies used indomethacin. There were no statistically significant differences between the very early treatment and expectant management groups with respect to time to full enteral feeds (MD 2.49 days; 95% CI ‐0.67 to 5.64; I<sup>2</sup> = 0%). </p> </section> <section id="CD013278-sec-0124"> <h6 class="title">Severe retinopathy of prematurity (ROP) (stage 3 or greater) (according to the international classification of ROP) </h6> <p>(<a href="./references#CD013278-fig-0043" title="">Analysis 2.18</a>) </p> <p>Four studies (n = 268) reported on this outcome. There were no statistically significant differences between the very early treatment and expectant management groups in severe ROP (typical RR 1.02, 95% CI 0.41 to 2.55; typical RD ‐0.02; 95% CI ‐0.07 to 0.03; I<sup>2</sup> = 36% for RR and 21% for RD, respectively). </p> <section id="CD013278-sec-0125"> <p><b>Subgroup analyses</b></p> <p>Two out of the four studies used indomethacin, one used ibuprofen and one study was a two‐center study that used indomethacin in one center and ibuprofen in the other. No significant differences in severe ROP were noted in the indomethacin only subgroup (typical RR 0.16, 95% CI 0.01 to 2.93; typical RD ‐0.03; 95% CI ‐0.09 to 0.02; test for heterogeneity not applicable for RR; I<sup>2</sup> = 12% for RD), ibuprofen only subgroup (typical RR 0.80, 95% CI 0.24 to 2.69; typical RD ‐0.03; 95% CI ‐0.21 to 0.15; test for heterogeneity not applicable), or the subgroup with use of either indomethacin or ibuprofen (typical RR 2.64, 95% CI 0.55, to 12.75; typical RD 0.09; 95% CI ‐0.05 to 0.23; test for heterogeneity not applicable). </p> </section> </section> <section id="CD013278-sec-0126"> <h6 class="title">Definite sepsis (clinical symptoms and signs of sepsis and a positive bacterial culture in a specimen obtained from normally sterile fluids or tissue obtained at postmortem) </h6> <p>(<a href="./references#CD013278-fig-0044" title="">Analysis 2.19</a>) </p> <p>Four studies (n = 260) reported on this outcome. There were no statistically significant differences between the very early treatment and expectant management groups in definite sepsis (typical RR 0.94, 95% CI 0.63 to 1.41; typical RD 0.01; 95% CI ‐0.07 to 0.09; I<sup>2</sup> = 0% for both RR and RD). </p> <section id="CD013278-sec-0127"> <p><b>Subgroup analyses</b></p> <p>Two out of the four studies used indomethacin and two used ibuprofen. No significant differences in definite sepsis were noted in the indomethacin only subgroup (typical RR 0.90, 95% CI 0.57 to 1.42; typical RD ‐0.04; 95% CI ‐0.20 to 0.12; I<sup>2</sup> = 0% for both RR and RD), or the ibuprofen only subgroup (typical RR 1.10, 95% CI 0.47, to 2.58; typical RD 0.03; 95% CI ‐0.07 to 0.12; I<sup>2</sup> = 0% for both RR and RD). </p> </section> </section> <section id="CD013278-sec-0128"> <h6 class="title">Oliguria (defined as less than 1 mL/kg/hour)</h6> <p>(<a href="./references#CD013278-fig-0045" title="">Analysis 2.20</a>) </p> <p>One study (n = 44) that used indomethacin reported on this outcome. There was no statistically significant difference between the very early treatment and expectant management groups in oliguria (typical RR 5.00, 95% CI 0.63 to 39.39; typical RD 0.18; 95% CI ‐0.01 to 0.38; test for heterogeneity not applicable). </p> </section> <section id="CD013278-sec-0129"> <h6 class="title">Duration of hospitalization (total length of hospitalization from birth to discharge home or mortality) (days) </h6> <p>(<a href="./references#CD013278-fig-0046" title="">Analysis 2.21</a>) </p> <p>Four studies (n = 240) reported on this outcome. There was a statistically significant difference between the very early treatment and expectant management groups with respect to duration of hospitalization favoring the very early treatment group (MD ‐5.35 days; 95% CI ‐9.23 to ‐1.47; I<sup>2</sup> = 57%). We rated the certainty of evidence as low. </p> <section id="CD013278-sec-0130"> <p><b>Subgroup analyses</b></p> <p>One out of the four studies used indomethacin, two used ibuprofen and one study was a two‐center study that used indomethacin in one center and ibuprofen in the other. No significant differences in duration of hospitalization were noted in the indomethacin only subgroup (MD ‐1.00 days; 95% CI ‐12.83 to 10.83; test for heterogeneity not applicable) or the subgroup with use of either indomethacin or ibuprofen (MD 38.00 days; 95% CI ‐5.66 to 81.66; test for heterogeneity not applicable). There was a statistically significant difference between the very early treatment and expectant management groups in the ibuprofen only subgroup with respect to duration of hospitalization favoring the very early treatment group (MD ‐6.27 days; 95% CI ‐10.39 to ‐2.14; I<sup>2</sup> = 59%). </p> </section> </section> <section id="CD013278-sec-0131"> <h6 class="title">Neurodevelopmental outcomes</h6> <section id="CD013278-sec-0132"> <p><b>Moderate/severe cognitive delay at 18 to 24 months</b></p> <p>One study (n = 79) that used indomethacin reported on this outcome. There was no statistically significant difference between the very early treatment and expectant management groups in moderate/severe cognitive delay (typical RR 0.27, 95% CI 0.03 to 2.31; typical RD ‐0.07; 95% CI ‐0.18 to 0.03; test for heterogeneity not applicable; <a href="./references#CD013278-fig-0047" title="">Analysis 2.22</a>). We rated the certainty of evidence as low. </p> </section> <section id="CD013278-sec-0133"> <p><b>Moderate/severe motor delay at 18 to 24 months</b></p> <p>One study (n = 79) that used indomethacin reported on this outcome. There was no statistically significant difference between the very early treatment and expectant management groups in moderate/severe motor delay (typical RR 0.54, 95% CI 0.05 to 5.71; typical RD ‐0.02; 95% CI ‐0.11 to 0.06; test for heterogeneity not applicable; <a href="./references#CD013278-fig-0048" title="">Analysis 2.23</a>). We rated the certainty of evidence as low. </p> </section> <section id="CD013278-sec-0134"> <p><b>Moderate/severe language delay at 18 to 24 months</b></p> <p>One study (n = 79) that used indomethacin reported on this outcome. There was no statistically significant difference between the very early treatment and expectant management groups in moderate/severe language delay (typical RR 0.54, 95% CI 0.10 to 2.78; typical RD ‐0.04; 95% CI ‐0.16 to 0.07; test for heterogeneity not applicable; <a href="./references#CD013278-fig-0049" title="">Analysis 2.24</a> ). We rated the certainty of evidence as low. </p> <p>None of the studies included in this comparison reported on pneumothorax, pulmonary hypertension or time to regain birth weight. Neurodevelopmental outcomes for cognitive, motor and language functions were reported separately (<a href="./references#CD013278-fig-0047" title="">Analysis 2.22</a>; <a href="./references#CD013278-fig-0048" title="">Analysis 2.23</a>; <a href="./references#CD013278-fig-0049" title="">Analysis 2.24</a>). </p> </section> </section> </section> </section> <section id="CD013278-sec-0135"> <h4 class="title">Comparison 3. Very early treatment versus early treatment</h4> <p>None of the trials included in this review reported on very early treatment versus early treatment </p> </section> <section id="CD013278-sec-0136"> <h4 class="title">Other subgroup and sensitivity analyses</h4> <p>Subgroup analyses based on choice of pharmacotherapy have been outlined within comparison 1 and 2. None of the trials were stratified based on the degree of hemodynamic significance of the PDA, hence this subgroup analysis was not possible. None of the trials specifically included infants less than 28 weeks or less than 1000 grams as predefined in our subgroup analyses. Three trials ( <a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>; <a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a>; <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>), included in the meta‐analysis enrolled infants &lt; 29 weeks of gestation. Since, each trial used a different pharmacotherapeutic option (indomethacin only in <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>, ibuprofen only in <a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a> and both indomethacin and ibuprofen in <a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>), we did not attempt to combine these three trials to create a new subgroup. Similarly given the small number of trials within each comparison and further within each subgroup, we refrained from conducting additional sensitivity analyses based on adequacy of trial methdology. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013278-sec-0137" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013278-sec-0137"></div> <section id="CD013278-sec-0138"> <h3 class="title" id="CD013278-sec-0138">Summary of main results</h3> <p>Fourteen RCTs completed to date have reported on 910 infants. Seven RCTs compared early treatment (defined as treatment initiated by seven days of age) versus expectant management and seven RCTs compared very early treatment (defined as treatment initiated by 72 hours of age) versus expectant management. Based on the choice of pharmacotherapy, the comparison of early treatment versus expectant management had two subgroups: intravenous/oral indomethacin (four studies; <a href="./references#CD013278-bbs2-0005" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]">Gersony 1983</a>; <a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a>; <a href="./references#CD013278-bbs2-0010" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78-81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013278-bbs2-0014" title="Van OvermeireB , Van De BroekH , Van LaerP , WeylerJ , VanhaesebrouckP . Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. Journal of Pediatrics2001;138(2):205-11. [DOI: 10.1067/mpd.2001.110528] [PMID: 11174617]">Van Overmeire 2001</a>), and intravenous/oral ibuprofen (three studies; <a href="./references#CD013278-bbs2-0001" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. Journal of Maternal-Fetal and Neonatal Medicine2013;26(4):423-9. [DOI: 10.3109/14767058.2012.733775] [PMID: 23057804]">Bagnoli 2013</a>; <a href="./references#CD013278-bbs2-0006" title="GhanemS , MostafaM , ShafeeM . Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. Journal of the Saudi Heart Association2010;22(1):7-12. [DOI: 10.1016/j.jsha.2010.01.002] [PMID: 23960586]">Ghanem 2010</a>; <a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a>); the comparison of very early treatment versus expectant management had three subgroups: intravenous/oral indomethacin only (four studies; <a href="./references#CD013278-bbs2-0002" title="CTRI/2009/091/000041. RCT comparing indomethacin vs. no treatment for PDA on the basis of size in the first 24 hrs of life in preterm neonates between 28 to 32 weeks gestation requiring assisted ventilation. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=318&amp;EncHid=&amp;modid=&amp;compid=%27,%27318det%272010. ">CTRI/2009/091/000041</a>; <a href="./references#CD013278-bbs2-0007" title="KaapaP , LanningP , KoivistoM . Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome. Acta Paediatrica Scandinavica1983;72(2):179-84. [DOI: 10.1111/j.1651-2227.1983.tb09693.x] [PMID: 6340412 ]">Kaapa 1983</a>; <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>; <a href="./references#CD013278-bbs2-0012" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>), and intravenous/oral ibuprofen only (two studies; <a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a>; <a href="./references#CD013278-bbs2-0011" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Chinese Journal of Contemporary Pediatrics2012;14(7):502-5. [PMID: 22809601]">Lin 2012</a>), and intravenous/oral indomethacin or intravenous/oral ibuprofen (one RCT; <a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>). The study by <a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a> did not contribute any data to the meta‐analysis. </p> <p>There was no significant difference between early treatment versus expectant management (no treatment initiated within the first seven days after birth) for a hemodynamically significant PDA for the primary outcome of ‘all‐cause mortality’ (moderate‐certainty evidence) or other clinically relevant outcomes such as surgical PDA ligation (very low‐certainty evidence), chronic lung disease (moderate‐certainty evidence), or severe IVH and NEC (low‐certainty evidence). Infants receiving expectant management in the first seven days after birth appeared to be significantly less likely to receive any PDA pharmacotherapy compared to early initiation of treatment (low‐certainty evidence). Among other outcomes, early treatment of hs‐PDA appeared to significantly shorten time to full enteral feeds as well as time to regain birth weight while significantly increasing the risk of oliguria compared to expectant management. There were no notable subgroup differences observed for this comparison. </p> <p>There was no significant difference between very early treatment versus expectant management (no treatment initiated within the first 72 hours after birth) for a hemodynamically significant PDA for the primary outcome of ‘all‐cause mortality’ (moderate‐certainty evidence) or other clinically relevant outcomes such as surgical PDA ligation, severe IVH and NEC (moderate‐certainty evidence), or chronic lung disease and neurodevelopmental impairment (low‐certainty evidence). Infants receiving expectant management in the first 72 hours after birth appeared to be significantly less likely to receive any PDA pharmacotherapy compared to very early initiation of treatment (very low‐certainty evidence). Very early treatment, however, appeared to significantly shorten the duration of hospitalization compared to expectant management (low‐certainty evidence). Among other outcomes, very early treatment of hs‐PDA appeared to significantly shorten the duration of mechanical ventilation while concomitantly increasing the exposure to postnatal corticosteroids compared to expectant management. The only clinically notable subgroup effect in this comparison was for the outcome of CLD. Very early treatment with ibuprofen appeared to significantly lower CLD while similar effects were not demonstrated in the other two subgroups. </p> </section> <section id="CD013278-sec-0139"> <h3 class="title" id="CD013278-sec-0139">Overall completeness and applicability of evidence</h3> <p>This is the first review comparing early treatment versus expectant management of a hemodynamically significant PDA in preterm infants. Though overall, expectant management appears to be a prudent option for the initial management of an hs‐PDA, being associated with less exposure to nonsteroidal anti‐inflammatory drugs without likely worsening relevant clinical outcomes, we recommend cautious interpretation and application of these findings due to several reasons. </p> <p>First, it is important to consider the variation in expectant management practices across trials before applying the results in clinical practice. For the expectant management arm, in this review, we did not differentiate between no treatment (or placebo) versus active non‐pharmacological measures to reduce the PDA shunt volume. Six out of the 14 trials used only placebo or no treatment in the expectant management arm and did not specify any other active non‐pharmacological measures (<a href="./references#CD013278-bbs2-0002" title="CTRI/2009/091/000041. RCT comparing indomethacin vs. no treatment for PDA on the basis of size in the first 24 hrs of life in preterm neonates between 28 to 32 weeks gestation requiring assisted ventilation. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=318&amp;EncHid=&amp;modid=&amp;compid=%27,%27318det%272010. ">CTRI/2009/091/000041</a>; <a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>; <a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a>; <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>; <a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a>; <a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a>). Three out of the 14 trials actively restricted fluid intake as a part of their conservative management strategy (<a href="./references#CD013278-bbs2-0001" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. Journal of Maternal-Fetal and Neonatal Medicine2013;26(4):423-9. [DOI: 10.3109/14767058.2012.733775] [PMID: 23057804]">Bagnoli 2013</a>; <a href="./references#CD013278-bbs2-0006" title="GhanemS , MostafaM , ShafeeM . Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. Journal of the Saudi Heart Association2010;22(1):7-12. [DOI: 10.1016/j.jsha.2010.01.002] [PMID: 23960586]">Ghanem 2010</a>; <a href="./references#CD013278-bbs2-0014" title="Van OvermeireB , Van De BroekH , Van LaerP , WeylerJ , VanhaesebrouckP . Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. Journal of Pediatrics2001;138(2):205-11. [DOI: 10.1067/mpd.2001.110528] [PMID: 11174617]">Van Overmeire 2001</a>), while the remaining five trials used medications such as loop diuretics and/or digoxin in addition to fluid restriction as a part of their conservative management strategy (<a href="./references#CD013278-bbs2-0005" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]">Gersony 1983</a>; <a href="./references#CD013278-bbs2-0007" title="KaapaP , LanningP , KoivistoM . Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome. Acta Paediatrica Scandinavica1983;72(2):179-84. [DOI: 10.1111/j.1651-2227.1983.tb09693.x] [PMID: 6340412 ]">Kaapa 1983</a>; <a href="./references#CD013278-bbs2-0010" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78-81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013278-bbs2-0011" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Chinese Journal of Contemporary Pediatrics2012;14(7):502-5. [PMID: 22809601]">Lin 2012</a>; <a href="./references#CD013278-bbs2-0012" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>). Given the overall paucity of trials and the use of multiple pharmacotherapeutic interventions we decided against attempts at further teasing out the effects of different non‐pharmacological expectant management strategies on clinical outcomes. It has been shown by <a href="./references#CD013278-bbs2-0079" title="MitraS , McNamaraPJ . Patent ductus arteriosus — time for a definitive trial. Clinics in Perinatology2020;47(3):617-39. [DOI: 10.1016/j.clp.2020.05.007] [PMID: 32713454]">Mitra 2020</a> that PDA closure rates in the placebo/no treatment arms of the placebo‐controlled trials of hs‐PDA treatment vary substantially (ranging from 0% to 78%) highlighting the wide variation in expectant management strategies used across trials. Thus, we acknowledge that variation in expectant management strategies across trials could potentially be an important contributor to heterogeneity thus lowering our certainty in the estimates for relevant clinical outcomes. </p> <p>Second, none of the trials were stratified based on the degree of hemodynamic significance of the PDA. There was wide variation in the definition of a hemodynamically significant PDA across trials. Hs‐PDA was defined in most trials based on characteristic clinical signs along with echocardiographic evidence of increased PDA shunt volume. However, the trials did not attempt to differentiate between PDAs with moderate versus high shunt volume based on any clinical or echocardiographic criteria. Hence, inclusion of all infants with PDA who fulfilled the current definition of hs‐PDA used in this review might have led to inclusion of a highly heterogeneous population in terms of their PDA shunt volume, especially more mature infants with a moderate volume PDA shunt where spontaneous PDA closure was highly likely. This could possibly explain why only a fraction of infants randomized to the expectant management groups required subsequent pharmacotherapy. Only four trials exclusively enrolled infants at less than 29 weeks of gestation (<a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>; <a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a>; <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>; <a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a>). Therefore, clinicians should exercise caution in applying these results to extremely preterm infants born at less than 28 weeks of gestation with a large PDA shunt documented on echocardiography. </p> <p>Early treatment appeared to shorten duration of parenteral nutrition and time to regain birth weight, while very early treatment appeared to reduce duration of hospitalization and mechanical ventilation. Such findings could be explained by early modulation of the PDA shunt volume using pharmacotherapy thereby improving systemic hypoperfusion as well as pulmonary hyperperfusion, respectively. However, early treatment was associated with increased risk of oliguria likely due to the effect of NSAIDs on glomerular filtration (<a href="./references#CD013278-bbs2-0049" title="AntonucciR , FanosV . NSAIDs, prostaglandins and the neonatal kidney. Journal of Maternal-Fetal &amp; Neonatal Medicine2009;22 Suppl 3:23-6. [DOI: 10.1080/14767050903184447] [PMID: 19701861]">Antonucci 2009</a>). It is unclear from the review whether this NSAID‐induced oliguria translated into longer‐term kidney injury in preterm infants. </p> <p>Infants receiving early treatment appeared to have a significantly higher exposure to postnatal corticosteroids. The trials included in this comparison were mostly at low risk of bias. Hence, higher use of postnatal corticosteroids in the very early treatment group is likely to be an unbiased co‐intervention secondary to physiological changes following very early treatment with NSAIDs. <a href="./references#CD013278-bbs2-0088" title="SchmidtB , RobertsRS , FanaroffA , DavisP , KirpalaniHM , NwaeseiC , et al. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). Journal of Pediatrics2006;148(6):730-4. [DOI: 10.1016/j.jpeds.2006.01.047] [PMID: 16769377]">Schmidt 2006</a> had demonstrated that prophylactic indomethacin independently increased need for supplemental oxygen and reduced postnatal weight loss thereby leading to worsened ventilatory status by the end of the first week of age. This could possibly explain increased use of postnatal corticosteroids in the very early treatment group. </p> <p>Subgroup analysis based on the choice of pharmacotherapy showed that very early treatment (within first 72 hours) with ibuprofen for an hs‐PDA significantly lowered CLD while such effects were not demonstrated with early treatment (initiated within the first seven days). Though these differences were observed in the respective subgroup analyses of two different comparisons, and therefore could have occurred by chance, one probable physiological explanation for this finding could be variation in treatment effectiveness in relation to ibuprofen pharmacokinetics. All ibuprofen trials included in this review used standard dose ibuprofen (10 mg/kg initial dose followed by two doses of 5mg/kg at 24 hour intervals). <a href="./references#CD013278-bbs2-0072" title="HirtD , Van OvermeireB , TreluyerJM , LanghendriesJP , MarguglioA , EisingerMJ , et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. British Journal of Clinical Pharmacology2008;65(5):629-36. [DOI: 10.1111/j.1365-2125.2008.03118.x] [PMID: 18307541]">Hirt 2008</a> demonstrated that to achieve therapeutic serum concentrations of ibuprofen beyond the first 72 hours of age, increasing doses of ibuprofen are required irrespective of gestational age. Therefore infants receiving treatment with standard dose ibuprofen beyond the first 72 hours might not have received optimal pharmacotherapy to close an hs‐PDA. In addition, <a href="./references#CD013278-bbs2-0087" title="SchenaF , FrancescatoG , CappelleriA , PicciolliI , MayerA , MoscaF , et al. Association between hemodynamically significant patent ductus arteriosus and bronchopulmonary dysplasia. Journal of Pediatrics2015;166(6):1488-92. [DOI: 10.1016/j.jpeds.2015.03.012] [PMID: 25882876]">Schena 2015</a> and <a href="./references#CD013278-bbs2-0076" title="LiebowitzM , KatheriaA , SauberanJ , SinghJ , NelsonK , HassingerDC , et al, PDA-TOLERATE (PDA: TOLEave it alone or Respond And Treat Early) Trial Investigators. Lack of equipoise in the PDA-TOLERATE trial: a comparison of eligible infants enrolled in the trial and those treated outside the trial. Journal of Pediatrics2019;213:222-6.e2. [DOI: 10.1016/j.jpeds.2019.05.049] [PMID: 31255386]">Liebowitz 2019</a> have shown that prolonged exposure to an hs‐PDA might increase the risk of CLD. This hypothesis was further tested in a post hoc analysis of the results of the PDA RCT (<a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a>), included in this review. <a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a> showed that infants who achieved successful PDA closure had lower risk of CLD and CLD/death compared to infants receiving placebo. Therefore, whether ‘early treatment’ should be defined as ensuring PDA shunt elimination using an appropriate pharmacotherapeutic agent versus mere provision of pharmacotherapy requires further research. </p> </section> <section id="CD013278-sec-0140"> <h3 class="title" id="CD013278-sec-0140">Quality of the evidence</h3> <p>The certainty of evidence for the primary outcome ‘all‐cause mortality’ was moderate according to GRADE for both comparisons (early treatment versus expectant management; very early treatment versus expectant management). Evidence for other clinical outcomes were of very low‐ to moderate‐certainty. The evidence was rated down for the following reasons. </p> <p>First, the overall risk of bias was judged as high for three trials (<a href="./references#CD013278-bbs2-0006" title="GhanemS , MostafaM , ShafeeM . Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. Journal of the Saudi Heart Association2010;22(1):7-12. [DOI: 10.1016/j.jsha.2010.01.002] [PMID: 23960586]">Ghanem 2010</a>; <a href="./references#CD013278-bbs2-0010" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78-81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013278-bbs2-0014" title="Van OvermeireB , Van De BroekH , Van LaerP , WeylerJ , VanhaesebrouckP . Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. Journal of Pediatrics2001;138(2):205-11. [DOI: 10.1067/mpd.2001.110528] [PMID: 11174617]">Van Overmeire 2001</a>) contributing to the early treatment versus expectant management comparison. The overall risk of bias was judged as low for two trials (<a href="./references#CD013278-bbs2-0005" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]">Gersony 1983</a>; <a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a>), and unclear for two trials (<a href="./references#CD013278-bbs2-0001" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. Journal of Maternal-Fetal and Neonatal Medicine2013;26(4):423-9. [DOI: 10.3109/14767058.2012.733775] [PMID: 23057804]">Bagnoli 2013</a>; <a href="./references#CD013278-bbs2-0009" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47 (suppl 1):88. ">Knight 2011</a>). For the comparison of very early treatment versus expectant management, the overall risk of bias was judged as low for four (<a href="./references#CD013278-bbs2-0003" title="De Waal K, PhadN , StubbsM , ChenY , KluckowM . A double blind, randomised controlled pilot trial of early pharmacological treatment versus supportive management in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2019;55:119. [DOI: 10.1111/jpc.14407_9]De WaalK , PhadN , StubbsM , ChenY , KluckowM . A randomized placebo-controlled pilot trial of early targeted non-steroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. Journal of Pediatrics 2020 August 25 [Epub ahead of print]. [DOI: https://doi.org/10.1016/j.jpeds.2020.08.062]">DeWaal 2020</a>; <a href="./references#CD013278-bbs2-0004" title="El-KhuffashA , BussmannN , BreatnachCR , SmithA , TullyE , GriffinJ , et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (the PDA RCT). Journal of Pediatrics 2020 Oct 15 [Epub ahead of print];S0022-3476(20)31291-9. [DOI: 10.1016/j.jpeds.2020.10.024]ISRCTN132881214. A randomised controlled trial of early targeted patent ductus arteriosus treatment using a risk-based severity score [Closing patent ductus arteriosus in preterm babies by using a risk-based score]. isrctn.com/ISRCTN13281214 (received 26 July 2016). [DOI: 10.1186/ISRCTN13281214]">EL‐Khuffash 2020</a>; <a href="./references#CD013278-bbs2-0008" title="KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal and Neonatal Edition2014;99(2):F99-104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52:102. [DOI: DOI: 10.1111/jpc.13194]">Kluckow 2014</a>; <a href="./references#CD013278-bbs2-0011" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Chinese Journal of Contemporary Pediatrics2012;14(7):502-5. [PMID: 22809601]">Lin 2012</a>), out of the seven trials and as high for the remaining three trials (<a href="./references#CD013278-bbs2-0002" title="CTRI/2009/091/000041. RCT comparing indomethacin vs. no treatment for PDA on the basis of size in the first 24 hrs of life in preterm neonates between 28 to 32 weeks gestation requiring assisted ventilation. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=318&amp;EncHid=&amp;modid=&amp;compid=%27,%27318det%272010. ">CTRI/2009/091/000041</a>; <a href="./references#CD013278-bbs2-0007" title="KaapaP , LanningP , KoivistoM . Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome. Acta Paediatrica Scandinavica1983;72(2):179-84. [DOI: 10.1111/j.1651-2227.1983.tb09693.x] [PMID: 6340412 ]">Kaapa 1983</a>; <a href="./references#CD013278-bbs2-0012" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>). Therefore, for some comparisons, more than 50% of the meta‐analytic weight was contributed by studies with unclear or high risk of bias. Hence, the certainty of evidence was rated down by one level for such comparisons. </p> <p>Second, substantial heterogeneity was noted for outcomes such as surgical PDA ligation, receipt of any pharmacotherapy and NEC (for the comparison of early treatment versus expectant management) as well as for the outcomes such as receipt of any pharmacotherapy, CLD and duration of hospitalization (for the comparison of very early treatment versus expectant management). The heterogeneity could only be partly explained by choice of pharmacotherapy. Given the possibility of other sources of heterogeneity unaccounted for in the analysis, the certainty of evidence was rated down for these outcomes for inconsistency. </p> <p>Third, most trials included in this review were small sample pilot trials with insufficient power to detect statistically significant differences in the rates of clinically relevant outcomes thereby leading to serious or very serious imprecision on GRADE assessment. </p> </section> <section id="CD013278-sec-0141"> <h3 class="title" id="CD013278-sec-0141">Potential biases in the review process</h3> <p>We are not aware of any potential biases in the review process. The authors were not involved with any of the included trials. </p> </section> <section id="CD013278-sec-0142"> <h3 class="title" id="CD013278-sec-0142">Agreements and disagreements with other studies or reviews</h3> <p>Some of the studies included in this review (<a href="./references#CD013278-bbs2-0001" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. Journal of Maternal-Fetal and Neonatal Medicine2013;26(4):423-9. [DOI: 10.3109/14767058.2012.733775] [PMID: 23057804]">Bagnoli 2013</a>; <a href="./references#CD013278-bbs2-0006" title="GhanemS , MostafaM , ShafeeM . Effect of oral ibuprofen on patent ductus arteriosus in premature newborns. Journal of the Saudi Heart Association2010;22(1):7-12. [DOI: 10.1016/j.jsha.2010.01.002] [PMID: 23960586]">Ghanem 2010</a>; <a href="./references#CD013278-bbs2-0011" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Chinese Journal of Contemporary Pediatrics2012;14(7):502-5. [PMID: 22809601]">Lin 2012</a>; <a href="./references#CD013278-bbs2-0013" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. Journal of Pediatrics2012;160(6):929-35.e1. [DOI: 10.1016/j.jpeds.2011.12.031] [PMID: 22284563]">Sosenko 2012</a>), have been included in a previous Cochrane Neonatal Review on use of ibuprofen for treatment of PDA (<a href="./references#CD013278-bbs2-0083" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2020, Issue 2. Art. No: CD003481. [DOI: 10.1002/14651858.CD003481.pub8]">Ohlsson 2020b</a>). Many of the studies have also been included in a previous systematic review and network meta‐analysis comparing pharmacotherapeutic options for treatment of a symptomatic PDA (<a href="./references#CD013278-bbs2-0078" title="MitraS , FlorezID , TamayoME , MbuagbawL , VanniyasingamT , VeronikiAA , et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA2018;319(12):1221-38. [DOI: 10.1001/jama.2018.1896] [PMID: 29584842]">Mitra 2018</a>). Previous meta‐analyses have shown that PDA pharmacotherapy is associated with significantly better PDA closure rates. However, improved rates of PDA closure did not appear to translate into longer‐term clinical benefit (<a href="./references#CD013278-bbs2-0078" title="MitraS , FlorezID , TamayoME , MbuagbawL , VanniyasingamT , VeronikiAA , et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA2018;319(12):1221-38. [DOI: 10.1001/jama.2018.1896] [PMID: 29584842]">Mitra 2018</a>; <a href="./references#CD013278-bbs2-0083" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2020, Issue 2. Art. No: CD003481. [DOI: 10.1002/14651858.CD003481.pub8]">Ohlsson 2020b</a>). </p> <p>Previous reviews, as mentioned above, have primarily focused on evaluating the effectiveness of therapy without taking into account the timing of treatment. It has been postulated that substantial use of open‐label pharmacotherapy in the placebo or no treatment group of included trials likely pulled the effect estimates for clinical outcomes towards the null thereby resulting in no statistically significant difference (<a href="./references#CD013278-bbs2-0091" title='SmithA , El-KhuffashAF . Defining "haemodynamic significance" of the patent ductus arteriosus: do we have all the answers?Neonatology2020;117(2):225-32. [DOI: 10.1159/000506988] [PMID: 32450558]'>Smith 2020</a>). Acknowledging the fact that the pragmatic design of the trials allowing open‐label treatment might have prevented us from drawing firm conclusions on the effectiveness of treatment on clinical outcomes, an important unanswered clinical question was whether early expectant management for an hs‐PDA can reduce exposure to any NSAID without worsening clinical outcomes. Therefore, in this review we specifically explored this clinical question. We found that early expectant management for an hs‐PDA reduced exposure to any NSAID without worsening clinical outcomes. However, our confidence in the certainty of these estimates is moderate to low, due to the factors mentioned previously. Our results are in keeping with the results of two recent RCTs on early treatment versus conservative management in preterm infants with a persistent hemodynamically significant PDA beyond the first week of age (<a href="./references#CD013278-bbs2-0018" title="ClymanRI , LiebowitzM , KaempfJ , ErdeveO , BulbulA , HÃƒÂ¥kanssonS , et al, PDA-TOLERATE (PDA: TO LEave it alone or Respond And Treat Early) Trial Investigators. PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age. Journal of Pediatrics2019;205:41-8.e6. [DOI: 10.1016/j.jpeds.2018.09.012] [PMID: 30340932]">Clyman 2019</a>; <a href="./references#CD013278-bbs2-0092" title="SungSI , LeeMH , AhnSY , ChangYS , ParkWS . Effect of nonintervention vs oral ibuprofen in patent ductus arteriosus in preterm infants: a randomized clinical trial. JAMA Pediatrics2020;174(8):1-9. [DOI: 10.1001/jamapediatrics.2020.1447] [PMID: 32539121]">Sung 2020</a>). Both trials found no difference in CLD or death with conservative management as compared to provision of pharmacotherapy in the second week of life. However, a post hoc secondary analysis of eligible infants treated outside the PDA‐TOLERATE trial (<a href="./references#CD013278-bbs2-0018" title="ClymanRI , LiebowitzM , KaempfJ , ErdeveO , BulbulA , HÃƒÂ¥kanssonS , et al, PDA-TOLERATE (PDA: TO LEave it alone or Respond And Treat Early) Trial Investigators. PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age. Journal of Pediatrics2019;205:41-8.e6. [DOI: 10.1016/j.jpeds.2018.09.012] [PMID: 30340932]">Clyman 2019</a>) due to lack of physician equipoise showed that the infants who were treated prior to six days of age had a significantly lower incidence of CLD (odds ratio (OR) 0.28; 95% CI: 0.11 to 0.68) and combined outcome CLD or death (OR 0.26; 95% CI: 0.11 to 0.63) in spite of having a significantly lower gestational age (<a href="./references#CD013278-bbs2-0076" title="LiebowitzM , KatheriaA , SauberanJ , SinghJ , NelsonK , HassingerDC , et al, PDA-TOLERATE (PDA: TOLEave it alone or Respond And Treat Early) Trial Investigators. Lack of equipoise in the PDA-TOLERATE trial: a comparison of eligible infants enrolled in the trial and those treated outside the trial. Journal of Pediatrics2019;213:222-6.e2. [DOI: 10.1016/j.jpeds.2019.05.049] [PMID: 31255386]">Liebowitz 2019</a>). Hence, further large trials are required to conclusively establish that early non‐pharmacological management is the approach of choice irrespective of the gestational age and degree of hemodynamic significance of the PDA. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013278-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD013278-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013278-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013278-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Early treatment vs expectant management, outcome: 1.1 All‐cause mortality during hospital stay." data-id="CD013278-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Early treatment vs expectant management, outcome: 1.1 All‐cause mortality during hospital stay. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Early treatment vs expectant management, outcome: 1.3 Receipt of any pharmacotherapy for a hemodynamically significant PDA." data-id="CD013278-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Early treatment vs expectant management, outcome: 1.3 Receipt of any pharmacotherapy for a hemodynamically significant PDA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Very early treatment vs expectant management, outcome: 2.1 All‐cause mortality during hospital stay." data-id="CD013278-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Very early treatment vs expectant management, outcome: 2.1 All‐cause mortality during hospital stay. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 1: All‐cause mortality during hospital stay" data-id="CD013278-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 1: All‐cause mortality during hospital stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 2: Surgical PDA ligation or transcatheter occlusion" data-id="CD013278-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 2: Surgical PDA ligation or transcatheter occlusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 3: Receipt of any pharmacotherapy for a hemodynamically significant PDA" data-id="CD013278-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 3: Receipt of any pharmacotherapy for a hemodynamically significant PDA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 4: Receipt of rescue medical treatment for a hemodynamically significant PDA" data-id="CD013278-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 4: Receipt of rescue medical treatment for a hemodynamically significant PDA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 5: Chronic lung disease" data-id="CD013278-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 5: Chronic lung disease</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 6: Duration of ventilator support (days)" data-id="CD013278-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 6: Duration of ventilator support (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 7: Duration of need for supplementary oxygen (days)" data-id="CD013278-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 7: Duration of need for supplementary oxygen (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 8: Postnatal corticosteroid use for CLD any time during hospital stay" data-id="CD013278-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 8: Postnatal corticosteroid use for CLD any time during hospital stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 9: Pneumothorax" data-id="CD013278-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 9: Pneumothorax</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 10: Intraventricular hemorrhage (IVH) (grades I to IV)" data-id="CD013278-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 10: Intraventricular hemorrhage (IVH) (grades I to IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 11: Severe intraventricular hemorrhage IVH (grades III and IV)" data-id="CD013278-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 11: Severe intraventricular hemorrhage IVH (grades III and IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 12: Periventricular leukomalacia (PVL; any grade)" data-id="CD013278-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 12: Periventricular leukomalacia (PVL; any grade) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 13: Necrotizing enterocolitis (NEC; stage 2 or greater)" data-id="CD013278-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 13: Necrotizing enterocolitis (NEC; stage 2 or greater) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 14: Spontaneous intestinal perforation" data-id="CD013278-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 14: Spontaneous intestinal perforation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 15: Time to full enteral feeds (postnatal age at time of achieving full enteral feeds)" data-id="CD013278-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 15: Time to full enteral feeds (postnatal age at time of achieving full enteral feeds) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 16: Time to regain birth weight (days)" data-id="CD013278-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 16: Time to regain birth weight (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 17: Severe retinopathy of prematurity (ROP)" data-id="CD013278-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 17: Severe retinopathy of prematurity (ROP) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 18: Definite sepsis" data-id="CD013278-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 18: Definite sepsis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Early treatment vs expectant management, Outcome 19: Oliguria" data-id="CD013278-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Early treatment vs expectant management, Outcome 19: Oliguria</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 1: All‐cause mortality during hospital stay" data-id="CD013278-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 1: All‐cause mortality during hospital stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 2: Surgical PDA ligation or transcatheter occlusion" data-id="CD013278-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 2: Surgical PDA ligation or transcatheter occlusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 3: Receipt of any pharmacotherapy for a hemodynamically significant PDA" data-id="CD013278-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 3: Receipt of any pharmacotherapy for a hemodynamically significant PDA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 4: Receipt of repeat courses of pharmacotherapy for a persistent hemodynamically significant PDA" data-id="CD013278-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 4: Receipt of repeat courses of pharmacotherapy for a persistent hemodynamically significant PDA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 5: Receipt of rescue medical treatment for a hemodynamically significant PDA" data-id="CD013278-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 5: Receipt of rescue medical treatment for a hemodynamically significant PDA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 6: Chronic lung disease" data-id="CD013278-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 6: Chronic lung disease </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 7: Duration of ventilator support (days)" data-id="CD013278-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 7: Duration of ventilator support (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 8: Duration of need for supplementary oxygen (days)" data-id="CD013278-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 8: Duration of need for supplementary oxygen (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 9: Postnatal corticosteroid use for CLD any time during hospital stay" data-id="CD013278-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 9: Postnatal corticosteroid use for CLD any time during hospital stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 10: Pulmonary hemorrhage" data-id="CD013278-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 10: Pulmonary hemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 11: Intraventricular hemorrhage (IVH) (grades I to IV)" data-id="CD013278-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 11: Intraventricular hemorrhage (IVH) (grades I to IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 12: Severe intraventricular hemorrhage IVH (grades III and IV)" data-id="CD013278-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 12: Severe intraventricular hemorrhage IVH (grades III and IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 13: Periventricular leukomalacia (PVL; any grade)" data-id="CD013278-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 13: Periventricular leukomalacia (PVL; any grade) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 14: Necrotizing enterocolitis (NEC; stage 2 or greater)" data-id="CD013278-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 14: Necrotizing enterocolitis (NEC; stage 2 or greater) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 15: Gastrointestinal bleeding within seven days of the first dose of pharmacotherapy" data-id="CD013278-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 15: Gastrointestinal bleeding within seven days of the first dose of pharmacotherapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 16: Spontaneous intestinal perforation" data-id="CD013278-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 16: Spontaneous intestinal perforation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 17: Time to full enteral feeds (postnatal age at time of achieving full enteral feeds)" data-id="CD013278-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 17: Time to full enteral feeds (postnatal age at time of achieving full enteral feeds) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 18: Severe retinopathy of prematurity (ROP)" data-id="CD013278-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 18: Severe retinopathy of prematurity (ROP) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 19: Definite sepsis" data-id="CD013278-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 19: Definite sepsis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 20: Oliguria" data-id="CD013278-fig-0045" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 20: Oliguria</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 21: Duration of hospitalization" data-id="CD013278-fig-0046" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 21: Duration of hospitalization </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 22: Neurodevelopmental impairment (moderate/severe cognitive delay) at 18‐24 months" data-id="CD013278-fig-0047" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 22: Neurodevelopmental impairment (moderate/severe cognitive delay) at 18‐24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 23: Neurodevelopmental impairment (moderate/severe motor delay) at 18‐24 months" data-id="CD013278-fig-0048" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 23: Neurodevelopmental impairment (moderate/severe motor delay) at 18‐24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013278-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/urn:x-wiley:14651858:media:CD013278:CD013278-CMP-002.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Very early treatment vs expectant management, Outcome 24: Neurodevelopmental impairment (moderate/severe language delay) at 18‐24 months" data-id="CD013278-fig-0049" src="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_t/tCD013278-CMP-002.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2: Very early treatment vs expectant management, Outcome 24: Neurodevelopmental impairment (moderate/severe language delay) at 18‐24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/media/CDSR/CD013278/image_n/nCD013278-CMP-002.24.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013278-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Early treatment compared to expectant management for preterm infants</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Early treatment compared to expectant management for preterm infants</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> preterm infants<br/><b>Setting:</b> Neonatal Intensive Care Unit<br/><b>Intervention:</b> early treatment (treatment of a hemodynamically significant PDA by seven days of age)<br/><b>Comparison:</b> expectant management (no treatment of a hemodynamically significant PDA in the first seven days after birth) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Expectant Management</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Early Treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality during hospital stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.46 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>500<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1,000<br/>(50 to 151) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of infants requiring surgical PDA ligation or transcatheter occlusion</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/>(0.65 to 1.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>432<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>156 per 1,000<br/>(94 to 261) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of infants receiving any pharmacotherapy for a hemodynamically significant PDA </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.30<br/>(1.86 to 2.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>232<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4 5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>989 per 1,000<br/>(799 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chronic lung disease</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/>(0.62 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>339<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>263 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1,000<br/>(163 to 339) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Severe Intraventricular hemorrhage (grades III and IV)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.32 to 2.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>171<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1,000<br/>(30 to 206) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Necrotizing enterocolitis (NEC; stage 2 or greater)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.34<br/>(0.86 to 6.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>473<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1,000<br/>(25 to 185) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> The CI included appreciable benefit and harm, therefore the certainty of evidence was rated down by one level for imprecision. </p> <p><sup>2</sup> &gt; 50% of meta‐analytic weight to studies with high or unclear risk of bias in one of sequence generation, allocation concealment, or blinding. Therefore, the certainty of evidence was rated by one level for risk of bias. </p> <p><sup>3</sup> I<sup>2</sup> value of 59% suggests there is moderate to substantial heterogeneity that cannot be explained by subgroup differences (test for subgroup differences P = 0.59). Therefore, the certainty of evidence was rated down by one level for inconsistency. </p> <p><sup>4</sup> There was high risk of bias for blinding in one study and low risk of bias across multiple domains for one study. </p> <p><sup>5</sup> Did not meet the optimal information size for detecting a 25% difference in benefit or harm (assuming a two‐sided alpha of 0.05 with 80% power). Therefore, the certainty of evidence was rated down by one level for imprecision. </p> <p><sup>6</sup> As there were few events from two small‐sample RCTs and the CI included appreciable benefit and harm, the certainty of evidence was rated down by two levels for imprecision. </p> <p><sup>7</sup> The CI included appreciable benefit favoring expectant management but crossed the threshold for no difference. Therefore, the certainty of evidence was rated down by one level for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Early treatment compared to expectant management for preterm infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013278-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Very early treatment compared to expectant management for preterm infants</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Very early treatment compared to expectant management for preterm infants</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> preterm infants<br/><b>Setting:</b> Neonatal Intensive Care Unit<br/><b>Intervention:</b> very early treatment (treatment of a hemodynamically significant PDA by 72 hours of age)<br/><b>Comparison:</b> expectant management (no treatment of a hemodynamically significant PDA in the first 72 hours after birth) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Expectant Management</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Very early treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality during hospital stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.58 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>384<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1,000<br/>(98 to 258) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of infants requiring surgical PDA ligation or transcatheter occlusion</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/>(0.36 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>293<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1,000<br/>(22 to 130) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of infants receiving any pharmacotherapy for a hemodynamically significant PDA </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.64<br/>(1.31 to 2.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>156<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>329 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>540 per 1,000<br/>(431 to 675) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chronic lung disease</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.63 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>384<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4 5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>378 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313 per 1,000<br/>(238 to 408) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Severe Intraventricular hemorrhage (grades III and IV)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.64<br/>(0.21 to 1.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>240<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1,000<br/>(14 to 128) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Necrotizing enterocolitis (NEC; stage 2 or greater)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/>(0.53 to 2.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>332<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1,000<br/>(44 to 183) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospitalization</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 5.35 lower<br/>(9.23 lower to 1.47 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>6 7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurodevelopmental outcomes (moderate/severe cognitive delay at 18 to 24 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.27<br/>(0.03 to 2.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>79<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1,000<br/>(3 to 225) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurodevelopmental outcomes (moderate/severe motor delay at 18 to 24 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54<br/>(0.05 to 5.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>79<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1,000<br/>(2 to 279) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurodevelopmental outcomes (moderate/severe language delay at 18 to 24 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54<br/>(0.10 to 2.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>79<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1,000<br/>(10 to 271) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> The CI included appreciable benefit and harm, therefore, the certainty of evidence was rated down by one level for imprecision. </p> <p><sup>2</sup> &gt; 50% of meta‐analytic weight from studies with high risk of bias in blinding personnel and outcome assessors </p> <p><sup>3</sup> I<sup>2</sup> value of 90% suggesting substantial heterogeneity that could not be explained by subgroup differences. Therefore, the certainty of evidence was rated down by two levels for inconsistency. </p> <p><sup>4</sup> I<sup>2</sup> value of 48% suggested there was moderate heterogeneity which is partly explained by subgroup differences (test for subgroup differences, P = 0.04). The certainty of evidence was therefore rated down by one level. </p> <p><sup>5</sup> The CI included appreciable benefit favoring very early treatment but crossed the threshold for no difference. Therefore, the certainty of evidence was rated down by one level. </p> <p><sup>6</sup> I<sup>2</sup> value of 57% suggested there was moderate to serious heterogeneity which is likely explained by subgroup differences. There was minimal overlap of CIs between the ibuprofen only subgroup vs the indomethacin/ibuprofen subgroup. The certainty of evidence was therefore rated down by one level. </p> <p><sup>7</sup> The CI includes benefit that may not be clinically meaningful (1.5 days reduction in hospitalization) as well as benefit that may substantially meaningful (9 days reduction in hospitalization). Therefore the certainty of evidence was rated down by one level for imprecision </p> <p><sup>8</sup> As there were few events in a small sample single RCT and the CI included appreciable benefit and harm, the certainty of evidence was rated down by two levels for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Very early treatment compared to expectant management for preterm infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/full#CD013278-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013278-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Early treatment vs expectant management</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality during hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.46, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.45, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.28, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Surgical PDA ligation or transcatheter occlusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.65, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.17, 3.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.66, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Receipt of any pharmacotherapy for a hemodynamically significant PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [1.86, 2.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [1.79, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [1.62, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Receipt of rescue medical treatment for a hemodynamically significant PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.27, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.27, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Chronic lung disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.62, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.52, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.56, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Duration of ventilator support (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.40 [‐30.15, 3.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Duration of need for supplementary oxygen (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.30 [‐43.27, 26.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Postnatal corticosteroid use for CLD any time during hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.37, 3.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Pneumothorax <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.32, 2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.15, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.30, 5.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Intraventricular hemorrhage (IVH) (grades I to IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.34, 2.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.21, 6.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.24, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Severe intraventricular hemorrhage IVH (grades III and IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.32, 2.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Periventricular leukomalacia (PVL; any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.55, 2.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [0.50, 12.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.38, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Necrotizing enterocolitis (NEC; stage 2 or greater) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.34 [0.86, 6.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.28, 8.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.89 [0.84, 9.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Spontaneous intestinal perforation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.14, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.06, 15.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.09, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Time to full enteral feeds (postnatal age at time of achieving full enteral feeds) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.80 [‐8.55, ‐1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Time to regain birth weight (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.40 [‐6.13, ‐0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Severe retinopathy of prematurity (ROP) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.44, 3.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.02, 5.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.51, 5.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Definite sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.68, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.56, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.61, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Oliguria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.41 [2.13, 19.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.59 [1.39, 15.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>39.00 [2.40, 633.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Early treatment vs expectant management</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013278-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Very early treatment vs expectant management</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality during hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.58, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.47, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.58, 3.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Intravenous/oral indomethacin or intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.17, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Surgical PDA ligation or transcatheter occlusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.36, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.07, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.36, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Intravenous/oral indomethacin or intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Receipt of any pharmacotherapy for a hemodynamically significant PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.31, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.10, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [1.77, 4.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Receipt of repeat courses of pharmacotherapy for a persistent hemodynamically significant PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [0.50, 7.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.29, 6.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [0.38, 130.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Receipt of rescue medical treatment for a hemodynamically significant PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.28, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.26, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Intravenous/oral indomethacin or intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.07, 16.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Chronic lung disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.63, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.61, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.35, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 Intravenous/oral indomethacin or intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.71, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Duration of ventilator support (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.75, ‐0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.37 [‐2.70, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐0.71, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 Intravenous/oral indomethacin or intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.00 [‐6.69, 18.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Duration of need for supplementary oxygen (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.73 [‐3.99, 0.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.61 [‐3.95, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.30 [‐11.83, 5.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Postnatal corticosteroid use for CLD any time during hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [1.12, 3.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.60, 6.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.53, 11.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.3 Intravenous/oral indomethacin or intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [0.89, 5.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Pulmonary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.30, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.22, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.24, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.3 Intravenous/oral indomethacin or intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.01, 8.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Intraventricular hemorrhage (IVH) (grades I to IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.44, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.27, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.41, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Severe intraventricular hemorrhage IVH (grades III and IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.21, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.07, 15.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.11, 3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.3 Intravenous/oral indomethacin or intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.10, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Periventricular leukomalacia (PVL; any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.31, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Necrotizing enterocolitis (NEC; stage 2 or greater) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.53, 2.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.18, 3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.42, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.3 Intravenous/oral indomethacin or intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.17 [0.35, 29.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Gastrointestinal bleeding within seven days of the first dose of pharmacotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.2 Intravenous/oral indomethacin or intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Spontaneous intestinal perforation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.15, 6.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.3 Intravenous/oral indomethacin or intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.17 [0.13, 75.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Time to full enteral feeds (postnatal age at time of achieving full enteral feeds) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [‐0.67, 5.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [‐0.67, 5.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.18 Severe retinopathy of prematurity (ROP) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.41, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.24, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.3 Intravenous/oral indomethacin or intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [0.55, 12.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.19 Definite sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.63, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.57, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.47, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.20 Oliguria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.63, 39.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.63, 39.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.21 Duration of hospitalization <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.35 [‐9.23, ‐1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.1 Intravenous/oral indomethacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐12.83, 10.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.2 Intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.27 [‐10.39, ‐2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.3 Intravenous/oral indomethacin or intravenous/oral ibuprofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>38.00 [‐5.66, 81.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.22 Neurodevelopmental impairment (moderate/severe cognitive delay) at 18‐24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.03, 2.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.23 Neurodevelopmental impairment (moderate/severe motor delay) at 18‐24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.05, 5.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.24 Neurodevelopmental impairment (moderate/severe language delay) at 18‐24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.10, 2.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Very early treatment vs expectant management</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013278.pub2/references#CD013278-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013278.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013278-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013278-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013278-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD013278-note-0010">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD013278-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013278-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013278-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013278-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013278\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013278\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013278\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013278\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013278\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013278.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013278.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013278.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013278.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013278.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718518234"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013278.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718518242"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013278.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd2461874f401',t:'MTc0MDcxODUxOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 